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Urinary tract infections (UTI) are among the most frequently reported infections among older 
persons.1-6 The incidence of UTI increases with age in both men and women7-9 and ranges 
from 12-29 per 100 person-years at risk in community-dwelling older people9,10 up to 44-58 
per 100 person-years at risk in long-term care facilities (LTCF).11,12 UTI account for 25% to 40% 
of all bacterial infections in LTCF.2,13-15 Infections in LTCF contribute to higher morbidity and 
mortality rates, to more infection outbreaks, higher antimicrobial use, and additional costs.1,16
However, it is still generally accepted that diagnosing UTI in vulnerable very old persons 
is challenging. Factors such as impaired communication due to dementia, high prevalence of 
incontinence, chronic genitourinary symptoms, and a high frequency of positive urine cul-
tures due to bacteriuria without complaints,17-19 makes diagnosing UTI even more difficult. 
In addition, since clinical symptoms of UTI are frequently absent,20 this makes differentiation 
between asymptomatic and symptomatic UTI in this population rather complicated.17,21 As a 
result, for LTCF populations, there is no generally accepted standard for the diagnosis of UTI. 
In these older residents, most clinical symptoms to ascertain UTI are based on consensus 
as presented in clinical guideliness.22-27 Currently, these guidelines define a clinical UTI as the 
presence of specific and non-specific symptoms and signs of UTI, such as dysuria, change in 
character of urine, and change in mental status, confirmed with a urinalysis to evaluate the 
evidence of the presence of nitrite and leukocyte esterase. A positive nitrite and leukocyte 
esterase test may indicate the presence of clinical UTI and treatment with antibiotics may 
start. Although UTI are often treated empirically,28 a urine culture may be necessary in LTCF 
residents with recurrent UTI to confirm the diagnosis and guide antibiotic treatment.
In vulnerable LTCF residents, clinical UTI not only cause several days of illness, but may have 
more severe consequences such as delirium, dehydration, urosepsis, hospitalization, or even 
death.4,29 Infections also lead to a general decline in functioning,30 which is often irreversible 
and can cause a cascade of general deterioration, more care dependency, and a higher mor-
tality risk. In addition, disability in activities of daily living (ADL) is independently associated 
with the development of infections.3,30,31 The relation between infections and ADL disability 
seems to present a negative spiral. Older people with dependency in ADL, depression, urine 
incontinence and impaired cognition are at higher risk of being admitted to a LTCF.32 
Different factors predispose older persons to infections, such as age-associated changes 
in the adaptive and innate immune system, the presence of multiple comorbid diseases, the 
use of indwelling devices (e.g. urinary catheter, feeding tubes), and 24-hour grouped living 
in close proximity (e.g. participating in social activities, and close contact between residents 
and staff ).28,33,34
Considering this negative impact of clinical UTI, we are particularly interested in how to 
prevent clinical UTI in vulnerable very old persons. Since the incidence of clinical UTI in LTCF 
residents is high, general hygienic precautions are important in these facilities, e.g. hand hy-
giene, toilet hygiene, timely change of incontinence material, and urinary catheter care.35,36 
Also, ensuring adequate fluid intake (hydration), regular toilet visits, and sufficient urination 
Chapter 1
10
(bladder emptying), is essential to eliminate bacteria and prevent UTI in this population.37 In 
addition, an adequate infection surveillance program can provide insight into the incidence 
and prevalence of infections in LTCF. Surveillance data should be frequently  monitored and 
reviewed to identify changing trends in infections.38,39 Surveillance results often provide tools 
for targeted infection prevention strategies. 
To more efficiently prevent clinical UTI and their subsequent negative consequences, it 
is important to identify older persons at risk for UTI. Among vulnerable older persons, an in-
creasing age,7,34 diabetes mellitus,40,41 stroke,42 urine incontinence,14,43,44 prior history of UTI,14,43 
and impaired functional and cognitive status3,30,31,34,43 are predictive for the development of 
clinical UTI. 
Several options are available to reduce the risk of clinical UTI in those at high risk. With 
the discovery of penicillin by Fleming in 1928 and, later, other antibiotics for the treatment of 
infections, it became possible to cure and prevent UTI. For many years preventive treatment 
with antibiotics was the regular preventive care. However, an increasing problem arose with 
uropathogens that became resistant to antibiotic treatment. Also, prophylactic prevention 
with antibiotics in residents with recurrent UTI is not preferred because of side-effects, antibi-
otic resistance, and the related costs.28,45 
With the expected increase in antimicrobial resistance there is a need for alternative non-
antibiotic methods for UTI prevention. Prophylaxis with the vaginal application of estrogens 
is effective in post-menopausal women, but its safety and feasibility in geriatric populations 
has not yet been studied.46,47 Methenamine hippurate is not effective for UTI prevention in 
patients with neurogenic bladder or renal tract abnormalities,48 but is often present in LTCF 
residents. Also, other non-drug preventive measures can be considered, such as vitamin C, 
Lactobacilli and cranberry. However, vitamin C was shown to be not effective in the preven-
tion of UTI,49 and the use of Lactobacilli in post-menopausal women had no effect in UTI pre-
vention compared with antibiotics.50 
Centuries ago American Indians were aware of the medicinal working of cranberries and 
cranberry-containing products have long been used as a folk remedy to prevent clinical UTI. 
However, the question remains: are cranberry capsules a new alternative for the prevention 
of clinical UTI in LTCF residents? There is some evidence that prophylaxis with cranberry prod-
ucts is a potential prevention strategy.51-55 Cranberries contain proanthocyanidins (PACs), 
which are stable compounds with anti-adhesion activity against e.g. Escherichia coli.56-58 Two 
studies reported that cranberry juice may be protective in older adults54,59 but the effective-
ness of cranberry capsules in the protection against clinical UTI in vulnerable very old persons 
in LTCF has not yet been studied. 
Aims of this thesis
The overall aim of this thesis is to study the possibilities for and effects of the prevention of 
clinical urinary tract infections in vulnerable very old persons. 
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The first part of this thesis investigates the effect of infections on functioning and explores 
which vulnerable very old persons would benefit most from UTI prevention. Chapter 2 de-
scribes a prospective follow-up study which explores the characteristics of LTCF residents on 
the natural course of care dependency. Within the Leiden 85-plus Study (a population-based 
prospective follow-up study of 85-year-old inhabitants of Leiden) we studied whether clinical 
infections predict an increase in disability in ADL among the oldest-old (Chapter 3), and which 
vulnerable older persons are at risk for UTI (Chapter 4). 
The second part of this thesis describes the results of the effectiveness and costs of cran-
berry capsule use in the prevention of UTI in LTCF residents. The CRANBERRY study, a double-
blind randomized placebo-controlled multi-center trial was conducted in 21 LTCF from the 
University Network for the Care sector in South Holland (UNC-ZH). The effectiveness of cran-
berry capsules in preventing UTI, stratified for UTI risk at baseline, is presented in Chapter 5. 
The use of cranberry capsules requires not only evaluation of its clinical  effectiveness but also 
of its cost-effectiveness. The economic evaluation presented in Chapter 6 investigated the ef-
fect of UTI on health and related costs, and whether the preventive use of cranberry capsules 
in LTCF is cost-effective. 
Chapter 7 presents a general discussion on the main results of the studies, considers the 
clinical implications of our findings for daily practice in long-term care, and makes some rec-
ommendations for future research.
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PART ONE
Correlates of clinical urinary tract infections

CHAPTER 2
Natural course of care dependency in 
residents of long-term care facilities: 
Prospective follow-up study 
Monique A.A. Caljouw, Herman J.M. Cools, Jacobijn Gussekloo
Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, 
The Netherlands
BMC Geriatrics 2014, 14:67 
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ABstrACt
Background Insight in the natural course of care dependency of vulnerable older persons 
in long-term care facilities (LTCF) is essential to organize and optimize individual tailored 
care. We examined changes in care dependency in LTCF residents over two 6-month periods, 
explored the possible predictive factors of change and the effect of care dependency on 
mortality.
Methods A prospective follow-up study in 21 Dutch long-term care facilities. 890 LTCF 
residents, median age 84 (Interquartile range 79–88) years participated. At baseline, 6 and 12 
months, care dependency was assessed by the nursing staff with the Care Dependency Scale 
(CDS), range 15–75 points. Since the median CDS score differed between men and women 
(47.5 vs. 43.0, P = 0.013), CDS groups (low, middle and high) were based on gender-specific 
33% of CDS scores at baseline and 6 months.
results At baseline, the CDS groups differed in median length of stay on the ward, urine 
incontinence and dementia (all P < 0.001); participants in the low CDS group stayed longer, 
had more frequent urine incontinence and more dementia. They had also the highest 
mortality rate (log rank 32.2; df = 2; P for trend <0.001). Per point lower in CDS score, the 
mortality risk increased with 2% (95% CI 1%-3%). Adjustment for age, gender, cranberry use, 
LTCF, length of stay, comorbidity and dementia showed similar results. A one point decrease 
in CDS score between 0 and 6 months was related to an increased mortality risk of 4% (95% 
CI 3%-6%). At the 6-month follow-up, 10% improved to a higher CDS group, 65% were in 
the same, and 25% had deteriorated to a lower CDS group; a similar pattern emerged at 
12-month follow-up. Gender, age, urine incontinence, dementia, cancer and baseline care 
dependency status, predicted an increase in care dependency over time.
Conclusion The majority of residents were stable in their care dependency status over 
two subsequent 6-month periods. Highly care dependent residents showed an increased 
mortality risk. Awareness of the natural course of care dependency is essential to residents 
and their formal and informal caregivers when considering therapeutic and end-of-life care 
options.
Keywords Care dependency, predictive factors, variability, mortality, long-term care 
facility, vulnerable older persons
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BACKground
The proportion of older people is steadily rising worldwide, people live longer and are manag-
ing their daily activities for longer than ever before.1 But they have also a higher risk on nega-
tive health outcomes, like care dependency, being institutionalized and mortality.2,3 Many vul-
nerable older people, heavily dependent on care, are living in long-term care facilities (LTCF) 
and place considerable constraints on healthcare professionals and healthcare budgets.
In the Netherlands 0.4% of the population; and around 2.7% of the population aged 65 
years and above are living in LTCFs.4,5 A typical Dutch LTCF accommodates 150–200 residents, 
has specialized psycho-geriatric wards for residents with dementia, somatic wards for resi-
dents with physical problems, and wards for rehabilitation.6
The daily nursing care in LTCF focuses on residents’ care dependency as a process in which 
the residents’ self-care decreases, and in which care demands make a person increasingly de-
pendent on nursing care.7 However, care dependency behaves like a dynamic process that is 
influenced by illness and disability,8-10 i.e. care dependency can be a temporary, long-term or 
a permanent state.11
Two recent studies investigated the natural course of activities in daily living (ADL) among 
nursing home residents. Both studies showed that residents could improve, be stable or de-
teriorate in their ADL performance during 6 months of follow-up.12,13 A study in a selected 
population of 68 females with Alzheimer’s disease, living in a single Dutch LTCF and who sur-
vived a two-year period, care dependency showed a significant increase within that two-year 
period.14
Previous studies have shown that i.e. nutritional status,12,13 cognitive impairment,12,13,15 
absence of daily contact with proxies,12 depression,12,16 neuropsychological deficits,17 incon-
tinence12,13,18 and infections19 were mentioned as predictors for deterioration in ADL perfor-
mance of vulnerable older people. Deterioration in ADL will lead to more individual care de-
mands and higher care dependency.
However, little is known about the natural course of care dependency in institutionalized 
older persons. It seems relevant to gain more insight in the stability and changes in care de-
pendency to manage care and to provide better tailored care for individual LTCF residents. 
Therefore, we examined the changes in care dependency in LTCF residents over two 6-month 
periods, explored the possible predictive factors of change in care dependency, and the effect 
of care dependency on mortality.
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Methods
setting and study population
The present prospective follow-up study was conducted within the framework of the CRAN-
BERRY trial. The CRANBERRY trial is a double-blind randomized placebo-controlled multi-
center trial, in which a total of 21 LTCFs from the University Nursing Home Research Network 
in South-Holland, the Netherlands, participated (trial registration NTR1266). The CRANBERRY 
study assesses the effectiveness of cranberry capsules to prevent urinary tract infections in 
vulnerable older persons living in intramural care settings in which care for the most vulner-
able older persons is provided by a multidisciplinary team including elderly-care physicians, 
nursing assistants, licensed practical nurses, registered nurses and paramedical professionals. 
Residents aged 65 years and over were included. Excluded were residents with a life expec-
tancy shorter than 1 month or using coumarin. For detailed information on the study design 
and outcomes we refer to the publication of the original trial.20
The Medical Ethics Committee of the Leiden University Medical Center approved the study. 
Written informed consent was obtained from all participants. For participants incapable of 
giving informed consent due to cognitive impairment, a guardian provided written consent.
Care dependency
At baseline, and at 6 and 12 months follow-up, an assessment was made of the care depen-
dency status by interviewing the responsible nurses who care for the participants. For this the 
Care Dependency Scale (CDS) was used, which is a tool completed by nursing staff for assess-
ment of the care dependency status of institutionalized residents.21 The CDS has satisfactory 
reliability and validity,22-24 and consists of 15 items, measuring basic care needs on a 5-point 
scale. The total CDS score ranges from 15 (completely dependent on care) to 75 (almost inde-
pendent of care). The CDS 15 items are eating and drinking, continence, body posture, mo-
bility, day and night pattern, getting (un)dressed, body temperature, hygiene, avoidance of 
danger, communication, contact with others, sense of rules and values, daily activities, recre-
ational activities and learning ability.
Since women and men differ in their baseline care dependency status and the CDS scores 
were not normally distributed, women and men were separately ranked into gender-specif-
ic 33% groups according to their baseline CDS score. Thereafter, we combined the lowest, 
middle and highest 33% for women and men, to generate three gender-specific CDS groups. 
The ‘low score’ CDS group indicates participants most dependent on care and the ‘high score’ 
CDS group indicates participants the most independent of care.
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Patient characteristics
Socio demographic factors
At baseline, a research nurse collected information on the participants’ gender, age and length 
of stay on the ward.
Comorbidity
Information on participants’ medical history was obtained by examination of the medical re-
cords, and interviews with the elderly care physician. Within the CRANBERRY trial we obtained 
clinical information on the presence of myocardial infarction, stroke, cancer, diabetes mellitus, 
chronic pulmonary disease (COPD) and dementia, as well as information on urine inconti-
nence and urinary tract infections in the preceding year.
statistical analysis
Comparisons were made between the CDS groups using Chi-square tests in case of categori-
cal data and Kruskal-Wallis tests to compare the three groups for non-normally distributed 
continuous variables. P-values < 0.05 were considered significant and should be interpreted 
as nominal ones.
The difference in the cumulative incidence of mortality between the CDS groups was ex-
plored with Kaplan-Meier curves, with corresponding log-rank test. Cox proportional hazards 
models, adjusted for age, gender, cranberry use, LTCF, length of stay on the ward, somatic co-
morbidity (myocardial infarction, stroke, cancer, diabetes mellitus, COPD, urine incontinence, 
and urinary tract infection in the preceding year) and dementia were used to present mortal-
ity risks based on continuous CDS score at baseline.
The change in care dependency for survivors between 0–6 months and 7–12 months is 
presented by the number of participants in the three CDS groups who improved, stayed sta-
ble, or degraded to another CDS group during the two 6-month periods. For the analysis of 
CDS change in the subsequent 7–12 months, participants were newly classified in gender-
specific 33% groups at the 6-month CDS assessment.
A crude and adjusted multivariate linear regression analysis was performed to estimate the 
predicted CDS score for survivors at 6-month follow-up. The CDS score at 6-month follow-up 
was considered as a dependent variable, while gender, age, cranberry use, LTCF, length of 
stay on the ward, CDS score at baseline, somatic comorbidity (myocardial infarction, stroke, 
cancer, diabetes mellitus, COPD, urine incontinence, and urinary tract infection in the preced-
ing year) and dementia were considered to be independent variables. Except gender and age, 
all other variables with a P-value ≥ 0.05 were excluded from the adjusted model. Co-linearity 
between the independent variables and dependent variable (CDS score at 6 months) will be 
investigated with the Variance Inflation Factor (VIF). A VIF of 5 or above indicates co-linearity.
Analyses were performed with IBM SPSS Statistics for Windows, version 20.0.
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results
In the original trial, 928 residents were included.20 In 38 participants the baseline CDS score 
was missing due to technical reasons, resulting in a total of 890 participants eligible for the 
present study. There were no differences is gender, age and comorbidity between the partici-
pants and the 38 non-participants.
At 6 months follow-up, 132 participants (14.8%) had died and in 44 participants (4.9%) 
the CDS scores were missing, resulting in 714 participants (80.2%) at 6 months. At 12 months 
follow-up, another 129 participants (18.1%) died and in 21 participants (2.9%) the CDS scores 
were missing, resulting in 564 participants with complete measurements (79.0%) at 12 months.
study population
Table 1 presents the baseline characteristics of the total population and of the three CDS 
groups. Overall, almost 75% of the study population was female and the median age was 84 
(IQR 79–88) years. The median CDS score was 44 (IQR 30–56). At baseline, women had a lower 
CDS score compared with men: 43 (33rd percentile 34, 66th percentile 51) vs. 47.5 (33rd per-
centile 37,66th percentile 55); Mann–Whitney U-test; P = 0.013.
There was no significant difference in age between the CDS groups (Kruskal-Wallis test; 
P = 0.180). The CDS score was negatively correlated with the length of stay on the ward: par-
ticipants who stayed the longest had the lowest CDS scores (Kruskal-Wallis test; P < 0.001). 
There were no significant differences between the CDS groups for cranberry use, myocardial 
infarction, stroke, cancer, diabetes mellitus, COPD and urinary tract infection in the preceding 
year. However, urine incontinence and dementia were more frequently present in the low CDS 
group compared with the other groups (Table 1).
Care dependency and mortality
Figure 1 presents the mortality rate for the three CDS groups; the highest mortality rate was in 
the group with the lowest CDS score (log rank 32.2; df = 2; P for trend <0.001).
The mortality risk at 12-month follow-up, based on continuous CDS scores at baseline are 
presented in Table 2. The crude analysis shows, that per point decrease in CDS score, the mor-
tality risk increased with 2% (HR 1.02; 95% CI 1.01-1.03). The adjusted models showed similar 
results.
Additional analysis showed that a one point decrease in CDS score between 0 and 6 months 
was related to an increased mortality risk of 4% during the subsequent 6 months follow-up, 
adjusted for baseline CDS score (HR 1.04; 95% CI 1.03-1.06).
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Change in care dependency during 12 months of follow-up
Table 3 shows the variation in care dependency among survivors for the CDS groups at 0–6 
months (n = 714) and 7–12 months (n = 564) follow-up, based on the 33% gender-specific 
CDS score at baseline for the first 6 months and 33% gender-specific CDS score at 6-month 
follow-up. The pattern of ‘improvement’, ‘being stable’ and ‘degradation’ of care dependency 
was almost similar over the two 6-month periods.
table 1. Baseline characteristics of the total study population and the three care dependency groups based on their care 
dependency scores at baseline
Care dependency groupsa
total 
population
low Cds 
group
Middle Cds 
group
high Cds 
group
n = 890 n = 303 n = 282 n = 305 P-value*
Cut-off level of the Cds score (points)
Men ≤ 37 points >37 - <55 ≥ 55 points
Women ≤ 34 points >34 - <51 ≥ 51 points
socio demographic factors
Female, n (%) 674 (75.7) 229 (75.6) 213 (75.5) 232 (76.1) 0.986
Age in years, median (IQR) 84 (79,88) 85 (79,89) 84 (79,88) 84 (79,88) 0.180**
Length of stay on ward in months, 
median (IQR)
18 (5,40) 31 (11,58) 17 (3,34) 12 (3,31) <0.001**
CDS: median (IQR) 44 (30,56) 26 (21,31) 44 (39,48) 60 (55,64) NA
Cranberry use 443 (49.8) 155 (51.2) 135 (47.9) 153 (50.2) 0.720
Comorbidities n (%)
Myocardial infarction 78 (8.8)b 28 (9.3) 28 (10.0) 22 (7.3) 0.482
Stroke 204 (23.1)b 79 (26.3) 63 (22.5) 62 (20.4) 0.215
Cancer 164 (18.7)b 49 (16.4) 49 (17.7) 66 (21.8) 0.209
Diabetes mellitus 174 (19.6) 54 (17.8) 54 (19.1) 66 (21.6) 0.484
COPD 129 (14.8)b 47 (15.8) 46 (16.5) 36 (12.1) 0.274
Urine incontinence 563 (65.8)b 263 (88.3) 180 (67.4) 120 (41.4) <0.001
Urinary tract infection preceding 
year
386 (43.4)b 136 (44.9) 120 (42.6) 130 (42.8) 0.817
Dementia 677 (76.8)b 262 (87.3) 224 (80.6) 191 (63.0) <0.001
CDS, Care Dependency Scale (range 15–75 points); IQR, interquartile range; COPD, chronic obstructive pulmonary disease; 
NA, not applicable.
aLow CDS group = most dependent on care; High CDS group = least dependent on care; bn = 1-17 missing; *Chi-square 
test;**Kruskal-Wallis test.
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figure 1. Cumulative mortality rate depending on care dependency scores at baseline during 12-months of follow-up 
Grey dotted line: low CDS-group; Black dotted line: middle CDS-group; Solid black line: high CDS-group.
table 2.  Mortality risk at 12-month follow-up depending on care dependency scores (continuous) at baseline
Mortality risk per 
point decrease in 
Cds score
95% Ci
Crude 1.02 1.01-1.03
Adjusted for age and gender 1.02 1.01-1.03
Adjusted for age, gender, cranberry use and LTCF 1.02 1.01-1.03
Adjusted for age, gender, cranberry use, LTCF, and length of stay on ward 1.02 1.01-1.03
Adjusted for age, gender, cranberry use, LTCF, length of stay on the ward and 
comorbiditya
1.03 1.02-1.04
Adjusted for age, gender, length of stay, cranberry use, LTCF comorbiditya and 
dementia
1.03 1.02-1.04
CDS, Care Dependency Scale (range 15–75 points); LTCF, Long-term care facility.
Data are presented as risk per point decrease (hazard ratio and corresponding 95% confidence intervals (CI)); estimated by 
Cox regression analysis.
aComorbidity (including myocardial infarction, stroke, cancer, diabetes mellitus, COPD, and urine incontinence, urinary tract 
infection preceding year).
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Predictive factors for increase in care dependency
Table 4 presents the results of the crude and adjusted multivariate linear regression analysis 
at 6 months. The adjusted model at 6 months showed that gender, age, baseline CDS score, 
table 3. Variation in care dependency in survivors during 2 subsequent periods of 6 months of follow-up for the three CDS 
groups
low Cds group Middle Cds group high Cds group total group
0-6 months: n (%)
n 233 236 245 714
Improved 41 (17.6) 30 (12.7) -- 71 (9.9)
Stable 192 (82.4) 120 (50.8) 155 (63.3) 467 (65.6)
Deterioration -- 86 (36.4) 90 (36.7) 176 (24.6)
7-12 months: n (%)
n 210 184 170 564
Improved 42 (20.0) 22 (12.0) -- 64 (11.3)
Stable 168 (80.0) 98 (53.3) 109 (64.1) 375 (66.5)
Deterioration -- 64 (34.8) 61 (35.9) 125 (22.2)
CDS, Care Dependency Scale (range 15–75 points).
table 4. Predictors of the care dependency score for survivors at 6-month follow-up (n = 659)
Crude modela Adjusted modelb
B se P-value B se P-value
Constant 22.37 5.18 <0.001 22.73 4.92 <0.001
Female 1.839 0.96 0.056 1.854 0.92 0.045
Age in years −0.106 0.06 0.058 −0.122 0.06 0.027
Cranberry use 0.143 0.78 0.855
Long-term care facility −0.079 0.04 0.055 −0.075 0.04 0.063
Length of stay on ward in months −0.009 0.01 0.486
Baseline CDS score 0.685 0.03 <0.001 0.693 0.03 <0.001
Myocardial infarction −0.819 1.38 0.552
Stroke −0.539 0.96 0.576
Cancer −2.927 1.01 0.004 −2.969 1.00 0.003
Diabetes mellitus 0.163 0.99 0.869
COPD 0.756 1.13 0.497
Urine incontinence −3.109 0.93 0.001 −3.171 0.92 0.001
Urinary tract infection preceding year −0.634 0.81 0.432
Dementia −3.779 1.03 <0.001 −3.543 0.97 <0.001
CDS, Care Dependency Scale (range 15–75 points); SE, Standard Error; COPD, Chronic obstructive pulmonary disease.
amultivariate linear regression model.
bexcluded from the model: cranberry use, myocardial infarction, stroke, diabetes mellitus, COPD, urinary tract infection 
preceding year.
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cancer, urine incontinence and dementia predicted an accelerated decrease of dependen-
cy scores at 6 months. Cranberry use, LTCF, myocardial infarction, stroke, diabetes mellitus, 
COPD, and urinary tract infection in the preceding year, were not associated with the CDS 
score at 6 months. We did not find co-linearity between the dependent variable (CDS-score at 
6 months) and the independent variables in both the crude and adjusted model. The Variance 
Inflation Factors ranges between 1.0 and 1.4. The multivariate linear regression model for men 
and women separately showed similar results (data not shown).
disCussion
The main purpose of this study was to gain insight in the stability and changes in the care 
dependency status of LTCF residents, to explore possible predictive factors of change in care 
dependency, and examine the effect of care dependency on mortality. Changes in care de-
pendency were examined to shed light on how to manage care and provide better tailored 
care for individual LTCF residents.
Care dependency and mortality
In studying the natural course of care dependency, the relation between care dependency 
and mortality is important. It can be hypothesized that higher care dependency leads to high-
er mortality risk. There are a few studies unraveling this relation. The study of Marengoni et al. 
showed that baseline disability was a strong predictor for mortality, independent of number 
of diseases.25 Also Chen et al. showed that the sum of care problems, independent of comor-
bidity, is a predictor of 12-month mortality in LTCF residents26, and Ferrucci et al. concluded 
that mortality after severe disability onset was high.27 Within our study, we found similar re-
sults. A one point decrease in baseline CDS score was related to a 2% higher mortality risk in 
the forthcoming 12-months, also when adjusting for age, gender, cranberry use, LTCF, length 
of stay on the ward, comorbidity and dementia.
the course of care dependency
A recent Swiss study among 10,199 nursing home residents (70% women, 74 % aged 80 years 
and above) observed a decrease in activities of daily living (ADL) of 35% and an increase in 
ADL of almost 14% among residents, within a period of median 6 months (SD 3 months).12 
They used the Minimum Data Set Activities of Daily Living (MDS-ADL) and looked at ADL per-
formance as primary outcome. Another study in low ADL-dependent LTCF residents in the 
USA, found that 69% of these LTCF residents with higher physical function remained stable 
in their ADL performance during 6 months of follow-up.13 Our study shows a similar trend for 
care dependency. The majority of the LTCF residents remained stable in their care dependen-
cy status, only 10% improved and 25% deteriorated. The variability in the pattern of ‘improve-
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ment’, ‘being stable’ and ‘degradation’ of care dependency varies in a similar pattern over two 
subsequent 6-month periods.
Predictors of change in care dependency
It is known that LTCF residents with cognitive impairment experience a deterioration in their 
ADL performance,12,13,15 which make them increasingly dependent on nursing care. As men-
tioned earlier, nutritional status,12,13 cognitive impairment,12,13,15 absence of daily contact with 
proxies,12 depression,12,16 neuropsychological deficits,17 incontinence12,13,18 and infections19 
were mentioned as predictors for deterioration in ADL performance. The study of Dijkstra et 
al. showed that the degree of care dependency at entry to the study was one of the strongest 
predictors of follow-up CDS ratings.14 Our study confirms that the baseline CDS score is predic-
tive, but showed also that gender, age, urine incontinence, dementia and cancer; predict an 
increase in care dependency over time.
strengths and limitations
The present study included a large sample of 890 residents residing in 21 Dutch LTCFs. Our 
study participants represent a vulnerable population; with a median age of 84 years and a 
high dependency on nursing care (median CDS score of 44 points). This median baseline CDS 
score is comparable with that of other studies in nursing homes.11,28 Because a recent inter-
national comparison of the CDS demonstrated its usefulness for comparative research across 
countries28, the results of the present study might be generalizable to LTCFs worldwide.
Daily nursing care in LTCF focuses on residents care dependency as a process in which the 
residents’ self-care decreases, and in which care demands makes a person increasingly depen-
dent on nursing care.7 Although other instruments to assess care dependency are available 
(e.g. the MDS-ADL, Barthel index,29 or Katz30) we decided to use the Care Dependency Scale. 
The CDS comprises all domains of nursing care; it is not limited to basic ADL, but also includes 
the individual’s capacity for social contacts, recreational activities, and learning abilities. The 
CDS is easy to administer, the responsible nurse could assess the CDS usually in less than five 
minutes and has shown satisfactory reliability and validity.22-24
Our study was nested in the CRANBERRY trial. Since the CRANBERRY study is a randomized-
controlled trial and half of the participants underwent treatment with cranberry, this could 
have influenced the course of care dependency. However, there was no cranberry effect on 
care dependency over time. Therefore the CRANBERRY trial gives us the possibility to explore 
whether there are predictive factors of changes in care dependency. However, this means that 
not all earlier mentioned predictors of change in ADL were included in the dataset.
Within this study we were particularly interested to explore the personal characteristics of 
LTCF residents on the natural course of care dependency. An institutional effect on mortality 
and care dependency was not found. Other factors dependent on organizational characteris-
tics of the long-term care facilities would be of interest for further research, since these char-
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acteristics could influence the care dependency status of LTCF residents as well. However, this 
was outside the scope of our study.
Another possible limitation of the present study is that we studied a selected period of 12 
months. Classification of the participants into the three CDS groups was based on the preva-
lent CDS score at baseline, and we have no data on the CDS score of the residents at admission 
to the LTCF. Because care dependency is a dynamic process, the change in CDS score (and 
therefore the results) might be different if we had known the care dependency status when 
the residents were first admitted.
implications for practice
A regular and simple assessment of care dependency can be valuable, since this allows nurs-
ing staff to become more aware of the variability in the care dependency status of their resi-
dents, manage care, and provide better tailored care for individual residents. In daily nursing 
care, they are the first professionals who might observe subtle changes in the care dependen-
cy status of residents and therefore can better anticipate residents’ care needs. The present 
study shows that residents can increase or as well as decrease in their level of care dependen-
cy. Care dependency may be influenced by individually tailored interventions and this needs 
further exploration in research. In addition, in view of the association between the CDS score 
and mortality, it seems relevant to train staff in providing palliative care as well as restorative 
care.31
ConClusions
The majority of surviving LTCF residents were stable in their care dependency status over 
two subsequent 6-month periods, even 10% showed improvement and 25% deteriorated in 
their dependency status. Highly care dependent residents showed an increased mortality risk. 
Awareness of the natural course of care dependency is essential to residents and their formal 
and informal caregivers when considering therapeutic and end-of-life care options.
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ABstrACt
Background Ageing is frequently accompanied by a higher incidence of infections and an 
increase in disability in activities of daily living (ADL).
objective This study examines whether clinical infections [urinary tract infections (UTI) 
and lower respiratory tract infections (LRTI)] predict an increase in ADL disability, stratified 
for the presence of ADL disability at baseline (age 86 years).
design The Leiden 85-plus Study. A population-based prospective follow-up study.
setting General population.
Participants A total of 154 men and 319 women aged 86 years.
Methods Information on clinical infections was obtained from the medical records. ADL 
disability was determined at baseline and annually thereafter during 4 years of follow-up, 
using the 9 ADL items of the Groningen Activity Restriction Scale.
results In 86-year-old participants with ADL disability, there were no differences in ADL 
increase between participants with and without an infection (−0.32 points extra per year; 
P = 0.230). However, participants without ADL disability at age 86 years (n = 194; 41%) had 
an accelerated increase in ADL disability of 1.07 point extra per year (P < 0.001). For UTIs, 
this was 1.25 points per year (P < 0.001) and for LRTIs 0.70 points per year (P = 0.041). In 
this group, an infection between age 85 and 86 years was associated with a higher risk to 
develop ADL disability from age 86 onwards [HR: 1.63 (95% CI: 1.04–2.55)].
Conclusions Among the oldest-old in the general population, clinically diagnosed 
infections are predictive for the development of ADL disability in persons without ADL 
disability. No such association was found for persons with ADL disability.
Keywords ADL disability, infections, oldest-old, general population, older people
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introduCtion
The oldest-old are predisposed to infectious diseases as a result of deterioration of the im-
mune system and an increased prevalence of co-morbidity.1 The incidence of urinary tract 
infections (UTIs) and lower respiratory tract infections (LRTIs) increase with age2-6, with an 
exponential increase in the oldest-old.5,6
In vulnerable older persons, the most common bacterial infection is a UTI, with serious 
adverse health consequences such as delirium, dehydration, urosepsis and hospitalisation.7,8 
Also, UTI has a high mortality rate, especially by hospitalisation.9 Community acquired pneu-
monia, also highly prevalent in older persons,10 is also a frequent cause of hospitalisation and 
death.11,12
Literature on the consequences of infections on the functional decline, also highly preva-
lent in older persons and increasing with age,13,14 is limited and mainly describes the impact 
of infections on the functional status of nursing home residents.15-17 To our knowledge, there 
is no information about how infections and activities of daily living (ADL) disability co-occur 
in the oldest-old in the general population. Therefore, this study examines whether incident 
clinical infections between age 85 and 86 years contribute to an increase in ADL disability 
from age 86 onwards, stratified for ADL disability at baseline.
Methods
setting and study population
The present study was conducted within the framework of the Leiden 85-plus Study. The 
Leiden 85-plus Study is an observational population-based prospective study of 85-year-old 
inhabitants of Leiden, The Netherlands. Between September 1997 and September 1999, all 
inhabitants of Leiden who reached the age of 85 years (birth cohort 1912–14) were invited to 
participate in the study. There were no selection criteria concerning health or demographic 
characteristics. The medical ethics committee of the Leiden University Medical Center ap-
proved the study. All participants gave informed consent for the entire study, including the 
use of data from their medical records for additional analyses, following explanation of the 
study requirements and assurance of confidentiality and anonymity. For participants with se-
vere cognitive impairment, a guardian gave informed consent.
Participants were visited annually until the age of 90 years. They were visited at their place 
of residence where face-to-face interviews were conducted, cognitive testing was performed 
and information on socio-demographic characteristics and disabilities in daily living were ob-
tained. Information on patients’ background was obtained annually from the medical records 
of general practitioners (GPs) and elderly care physicians.
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infections
Information on clinical infections was obtained from the medical records. UTIs were consid-
ered present when the treating GP or elderly care physician diagnosed UTI based on signs and 
symptoms and urine analysis.18 LRTI was clinically diagnosed by the treating physician based 
on medical history taking, physical examination and clinical judgment during a consultation 
with the participant.10
Adl disability
ADL disability was measured annually with the nine ‘basic activities of daily living’ from the 
Groningen Activity Restriction Scale (GARS),19 by face-to-face interviews. ADL included the fol-
lowing tasks: getting around the house, getting into and out of bed, standing up from a chair, 
going to the toilet, dressing oneself, washing hands and face, washing whole body, preparing 
breakfast and drinking and feeding oneself. Answers ranged from ‘fully independently, with-
out any difficulty’ (1 point) to ‘not fully independently, only with someone’s help’ (4 points); 
total score ranged from 9 to 36.19 Higher scores indicate more ADL disability. ADL disability 
was considered present when the participant was unable to do at least one of the nine ADL 
items independently (GARS > 9 points).
socio-demographic factors
During baseline interviews, a research nurse collected information about the participants’ 
residency, income, level of education and smoking habits.
Mental status
Cognitive function was measured by the Mini-Mental State Examination (MMSE). Scores 
ranged from 0 to 30, with lower scores indicating impaired cognitive functioning. Severe cog-
nitive impairment was defined as an MMSE score ≤ 19 points.20 To determine the presence of 
depressive symptoms, the Geriatric Depression Scale-15 (GDS-15) was conducted. Depressive 
symptoms were considered present by a GDS-15 score ≥ 4 points,21-23 but only in those with 
MMSE ≥ 19 points.
Co-morbidity
Information on participants’ medical history was obtained by standardised interviews with 
their treating GP or elderly care physician, and by examination of the medical records, in-
cluding data on the presence of myocardial infarction, stroke, diabetes mellitus, and chronic 
obstructive  pulmonary disease (COPD). Information on incontinence and musculoskeletal 
complaints was collected in face-to-face interviews with the participants.
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statistical analysis
Differences in baseline characteristics at age 86 years, stratified for ADL disability, between the 
infection and no infection groups, were compared with a Chi-square test or Fisher’s exact test 
when the cells in the 2 × 2 crosstabs were < 10 observed or 5 expected counts, for categorical 
data. Median scores of the GARS were compared using the Mann–Whitney U test. P-values < 
0.05 were considered statistically significant.
Short-term effect: retrospective analysis
The short-term effect of infections on ADL disability was studied retrospectively, using ‘history 
of UTI or LRTI between age 85 and 86 years’ in relation to ADL disability scores at age 85 and 
86 years. The short-term effect of infections on ADL disability was calculated by taking the 
delta in the ADL score (ADL score at 86 years minus the ADL score at 85 years), stratified for 
participants with and without ADL disability at age 86 years. The independent t-test was used 
to test differences in the mean increase in ADL scores between participants with and without 
infections for both groups.
Long-term effect: prospective analysis
We started the follow-up for 4 years at age 86 years to enable to study the ‘history of UTI or 
LRTI between age 85 and 86 years’ as a possible predictor for long-term ADL disability from 
age 86 years onwards. All analyses were stratified for ADL disability at age 86 years. 
Cox regression models were used to analyse whether an infection between age 85 and 
86 years was associated with the long-term development of ADL disability from 86 years on-
wards in those without ADL disability at 86 years.
The relation between infections, between age 85 and 86 years, and changes in ADL disabil-
ity scores over time (4 years of follow-up) were analysed with linear mixed models (LMM). Each 
LMM included a term for the baseline difference in the ADL disability score for those with and 
without infection between age 85 and 86 years, a term for time, and a term for the interaction 
between infection and time. The effect of time on ADL disability reflects the annual change in 
ADL disability in those without infection, and is presented as the basic annual change in the 
ADL disability score (β2). The interaction of infection and time reflects the additional annual 
change in ADL disability for those with infection and is presented as additional annual change 
in the ADL disability score (β3).
Cox regression and LMM were adjusted for gender, living situation (independent or long-
term care facility) and comorbidity (myocardial infarction, stroke, diabetes mellitus, COPD, 
musculoskeletal complaints and incontinence). 
Analyses were performed with SPSS for Windows, version 17.0 (SPSS, Inc., Chicago, IL, USA).
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results
Between September 1997 and September 1999, 705 participants were eligible for participa-
tion in the Leiden 85-plus Study. Ninety-two participants refused to participate and 14 partici-
pants died before enrolment, resulting in a study population of 599 participants at the age of 
85 years (response rate 87%). At age 86 years, the baseline of the present study, 551 partici-
pants are still alive. A total of 72 participants for whom valid clinical information on infections 
at the age of 86 years was missing were excluded. For six participants information on ADL 
disability at 86 years was missing, resulting in a final study population of 473 participants. The 
78 participants that were not included in the present study more often had primary school 
education only, myocardial infarction, COPD and incontinence (data not shown).
study population
Table 1 presents a comparison of the characteristics of the participants with and without in-
fections between age 85 and 86 years (n = 473), at the age of 86 years stratified for partici-
pants with and without ADL disability at the age of 86 years. Almost 70% of the study popula-
tion was female. In participants without ADL disability at baseline, on all but one there were 
no significant differences in sociodemographic factors and functioning for both the infection 
and no-infection group. Only for current smoking, a significant difference between the infec-
tion and no-infection group (28 versus 12%; P = 0.030) was found. In participants with ADL 
disability, more participants in the infection group were living in long-term care facilities than 
in the no-infection group (48 versus 27%, P = 0.001). In this group of participants with ADL 
disability, participants with an infection between 85 and 86 years had a significantly higher 
median ADL baseline score compared with those without infections (16 versus 13 points; P < 
0.001). In both strata, there was a higher occurrence of COPD in participants with infections 
(participants without ADL disability: infection 28% versus no-infection 6%; P = 0.001), and in 
participants with ADL disability:  infection 17 versus 7%; P = 0.009. In the participants with 
ADL disability, there was significantly more incontinence among those participants with in-
fection (68 versus 51%; P = 0.013).
short-term consequences: retrospective analysis
Table 2 presents the 1-year increase in ADL disability score from age 85 to 86 years for partici-
pants with and without ADL disability at age 86 years. In participants without ADL disability, 
32 (16.5%) had at least one infection versus 75 (26.9%) in participants with ADL disability 
(P = 0.008). 
In participants with ADL disability at age 86 years, the mean increase in ADL scores was 
similar in participants with an infection (UTI or LRTI) and without an infection (2.28 versus 
2.52 points increase; independent t-test, P = 0.809). In participants without ADL disability at 
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the age of 86 years, the mean increase in ADL scores was also similar for participants with and 
without infection (independent t-test, P = 0.594). 
long-term consequences: prospective analysis
In participants without ADL disability at baseline (n = 194), an infection (UTI or LRTI) between 
the ages of 85–86 years was associated with higher risk to develop ADL disability from age 
86 onwards [HR: 1.63 (95% CI: 1.04– 2.55)]. After adjustment for gender, living situation and 
comorbidity this risk remained roughly similar [HR: 1.70 (95% CI: 1.03–2.81)].
For UTI and LRTI, the unadjusted HRs were 1.66 (95% CI: 0.95–2.90) and 1.43 (95% CI: 0.75–
2.73), respectively. After adjustment these, HRs remained similar (data not shown).
The changes in ADL disability scores over time for those with and without infection, with 
and without UTI, and with and without LRTI, are presented in Figure 1, stratified for ADL dis-
ability at the age of 86 years. In all groups, ADL disability increased with age. 
In participants with ADL disability at baseline, the difference in the ADL score between 
the infection and no-infection group at baseline was 4.52 points (P < 0.001). No accelerated 
increase was found in this group for those with an infection compared with those without: 
additional annual change −0.32 points, (95% CI: −0.85–0.21, P = 0.230) (Figure 1).
Among the participants without ADL disability at baseline, participants with an infection 
(UTI or LRTI) between age 85 and 86 years had an accelerated increase in ADL disability (1.07 
points extra per year, 95% CI: 0.61–1.53, P < 0.001) compared with those without infections 
(Figure 1). The accelerated increase in ADL disability was 1.25 points extra per year (95% CI: 
0.66–1.83, P < 0.001) for UTI and 0.70 points extra per year (95% CI: 0.03–1.38, P = 0.041) for 
LRTI. After adjustment for gender, living situation (independent or long-term care facility) and 
comorbidity, these estimates remained similar, still significant and the conclusions were un-
changed (data not shown).
table 2. Short-term change in ADL score (delta between the ages of 85-86 years) depending on the presence of infections 
between 85 and 86 years
no Adl disability at 86 years, 
n = 194 (gArs = 9)a
Adl disability at 86 years, 
n = 279 (gArs > 9)a
n % Mean Adl-increase 
(sd) 85-86
P-valueb n % Mean Adl increase 
(sd) 85-86
P-valueb
No-infection 162 83.5 -0.42 (1.10) 204 73.1 2.52 (8.18)
At least one infection 
(UTI or LRTI)
32 16.5 -0.53 (0.98) 0.594 75 26.9 2.28 (5.02) 0.809
UTI 17 8.8 -0.53 (1.07) 0.740 55 19.7 2.53 (5.17) 0.962
LRTI 15 7.7 -0.53 (0.92) 0.715 30 10.8 1.83 (4.62) 0.627
UTI, Urinary Tract Infection; LRTI, Lower Respiratory Tract Infection; SD, standard deviation; ADL,  Activities of Daily Living; 
GARS,  Groningen Activity Restriction Scale 
aADL disability measured with the 9-item Groningen Activity Restriction Scale (9-36)
bIndependent t-test; no-infection group compared with infection groups 
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disCussion
The present study shows that, in the general population of the oldest-old, clinically diagnosed 
infections are predictive for the development of ADL disability for persons without ADL dis-
ability at the age of 86 years. Moreover, clinically diagnosed infections contribute to an ac-
celerated increase in ADL disability on the long term. No such association was found for those 
with ADL disability at baseline.
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figure 1. Change in the ADL score over time for those with and without an infection between the ages of 85-86  years (A), 
with and without UTI (B) and with and without LRTI (C), stratified for ADL disability at age 86 years.
Linear mixed models in which β3 is the additional annual change in ADL disability score for those with infection between 
ages 85-86 years. 
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Our results build on evidence from studies involving patients in selected populations of 
nursing home residents.15-17 Bula et al. showed a higher risk of a decline in the functional sta-
tus in older nursing home residents with an infection (mean age 85.7 years, 76.6% female).15 
Barker et al. found a decrease in functioning in older persons living in long-term care facilities 
within 3–4 months after an influenza infection.16 However, in contrast to the previous studies, 
Loeb et al. found no significant effect in a follow-up period of 3 years on the functional status 
in nursing home residents, neither for pneumonia nor LRTIs compared with controls (mean 
age 86.1 years, 75.5% female).17 Our study is the first to focus on the consequences of infec-
tions on ADL disability in the oldest-old in the general population.
Interestingly, in a previous analysis in the Leiden 85-plus Study, we found that chronic 
multimorbidity predicts an accelerated increase in ADL disability in very old persons with a 
good cognitive function.24 This study shows that also an acute illness predicts an accelerated 
increase in ADL disability in the oldest-old without ADL disability at 86 years.
The present study is based on a unique sample of participants aged ≥ 86 years. The pop-
ulation-based study structure and almost complete follow-up of the participants allow us to 
generalise our results to the oldest-old in the general population. All infections were clinically 
diagnosed by GPs and elderly care physicians. This procedure reflects usual care and enables 
generalisation of our results to daily clinical care for the oldest-old.
A limitation of our study is that we only have information on infections per year and do not 
know the precise date the infection occurred.
ConClusion
This study shows that in older persons without ADL disability at 86 years of age, clinical infec-
tions (UTI and LRTI) predict the development of ADL disability from age 86 onwards. These 
infections may be used in the future as a predictor for ADL disability in the oldest-old who are 
not yet disabled. The GP or elderly care physician should be vigilant when older persons with-
out ADL disability get infections and may start active functional rehabilitation to maintain 
independence in ADL. Future studies may also address whether the prevention of infections, 
a quick recovery after infections and functional rehabilitation are beneficial in the oldest-old 
in the general population to maintain independence in ADL and to avoid adverse health out-
comes.
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Key points
• Ageing is frequently accompanied by a higher incidence of infections and an increase 
in disability in activities of daily living.
• In 86-year-old persons without ADL disability, an infection was associated with a high-
er risk to develop ADL disability.
• In disabled 86-year-old persons, there were no differences in ADL increase between 
participants with and without an infection.
• Among the oldest-old in the general population, infections are predictive for the devel-
opment of ADL disability. 
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ABstrACt
Background Urinary tract infections (UTI) are common among the oldest old and may 
lead to a few days of illness, delirium or even to death. We studied the incidence and 
predictive factors of UTI among the oldest old in the general population.
Methods The Leiden 85-plus Study is a population-based prospective follow-up study of 
86-year-old subjects in Leiden, The Netherlands. Information on the diagnosis of UTI was 
obtained annually during four years of follow-up from the medical records and interviews 
of treating physicians. A total of 157 men and 322 women aged 86 years participated in 
the study. Possible predictive factors were collected at baseline, including history of UTI 
between the age of 85 and 86 years, aspects of functioning (cognitive impairment (Mini-
Mental State Examination (MMSE) < 19), presence of depressive symptoms (Geriatric 
Depression Scale (GDS) > 4), disability in activities of daily living (ADL)), and co-morbidities. 
results The incidence of UTI from age 86 through 90 years was 11.2 (95% confidence 
interval (CI) 9.4-13.1) per 100 person-years at risk. Multivariate analysis showed that history 
of UTI between the age of 85 and 86 years (hazard ratio (HR) 3.4 (95% CI 2.4-5.0)), impaired 
cognitive function (HR 1.9 (95% CI 1.3-2.9)), disability in daily living (HR 1.7 (95% CI 1.1-
2.5)) and urine incontinence (HR 1.5 (95% CI 1.0-2.1)) were independent predictors of an 
increased incidence of UTI from age 86 onwards. 
Conclusions Within the oldest old, a history of UTI between the age of 85 and 86 years, 
cognitive impairment, ADL disability and urine incontinence are independent predictors of 
developing UTI. These predictive factors could be used to target preventive measures to the 
oldest old at high risk of UTI.
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BACKground
Urinary tract infections (UTIs) are common in the very elderly and account for nearly 25% of all 
infections.1,2 The incidence of UTI increases with age in both men and women,3-5 and increases 
from 12 to 29 per 100 person-years at risk in community-dwelling elderly populations5,6 to 44 
to 58 per 100 residents per year at risk in long term care facilities.7,8 These UTI are often com-
plicated, involving the presence of structural or functional abnormalities of the genitourinary 
tract.9 Especially in vulnerable older persons living in long term care facilities, UTIs more often 
have serious consequences such as delirium, dehydration, urosepsis, hospitalisation, or even 
death.10,11
Several strategies to prevent UTI have been developed, such as treatment of those at high 
risk with low-dose, long-term antibiotics,12,13 oestrogens14 and cranberry products.12,15 These 
strategies have been shown to be effective in preventing UTI in younger women with recur-
rent UTI13-15, but not yet in vulnerable older people. Preventive strategies are best applied to 
those at risk; however, factors associated with UTI in ambulatory older patients in the com-
munity setting have not been described.
Previous studies have shown that increasing age,4,16 diabetes mellitus,17,18 stroke,19 urine 
incontinence,1,20,21 prior history of UTI,1,20 urogenital surgery,1,20 and impaired functional and 
cognitive status16,20 predict the development of UTI among older individuals. However, these 
studies investigated predictors of UTI in specific patient groups, such as hospitalised patients 
and patients residing in long-term care facilities and did not include older individuals in the 
general population. In addition, these studies used different methods to identify UTI. It is gen-
erally accepted that diagnosing symptomatic UTI in older persons is complicated due to fac-
tors like difficult doctor-patient communication, chronical genito-urinary symptoms, and a 
high frequency of positive urine cultures due to bacteriuria without complaints.22 
To target preventive strategies against UTIs in older individuals, those with highest risk to 
develop UTI have to be identified. The purpose of this study was to determine the incidence 
and predictive factors of UTI among the oldest old in the general population. 
Methods
setting and study population
The Leiden 85-plus Study is an observational population-based prospective study of 85-year-
old inhabitants of Leiden, The Netherlands. Between September 1997 and September 1999, 
all inhabitants of Leiden who reached the age of 85 years were invited to participate in the 
study. There were no selection criteria concerning health or demographic characteristics. The 
medical ethics committee of the Leiden University Medical Center approved the study. All 
participants gave informed consent for the whole study including the use of data from their 
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medical records for additional analysis, following explanation of the study requirements and 
assurance of confidentiality and anonymity. For participants with severe cognitive impair-
ment, a guardian gave informed consent.
The present study was conducted within the framework of the Leiden 85-plus Study. We 
started follow-up for four years at age 86 years to allow us to study ‘history of UTI between the 
age of 85 and 86 years’ as a possible predictor. In this study, 479 participants aged 86 years 
were included. Participants were revisited annually until the age of 90 years. All participants 
were visited at their place of residence where face-to-face interviews were conducted, cogni-
tive testing was performed, information on socio-demographic characteristics and disabilities 
in daily living was obtained, and a venous blood sample was taken. 
urinary tract infection
The endpoint of this study was the development of the first UTI from age 86 through 90 years. 
This endpoint was considered present when treating physicians diagnosed UTI based on signs 
and symptoms and urine analysis. 
The endpoint was also reached when a participant during follow-up died from UTI. General 
practitioners and elderly care physicians were interviewed annually to gather clinical informa-
tion. Each year data were gathered about the development of clinical diagnosed UTI during 
the preceding year from clinician interviews and records. Mortality data were obtained from 
the municipality. Specific data on causes of death were obtained from Statistics Netherlands, 
according to the International Classification of Diseases and Related Disorders, 10th revision 
(ICD-10), including UTI (ICD-10 code N39.0).23 
selection of potentially predictive factors
Through an extensive search of scientific literature, factors that are potentially predictive for 
UTI in older individuals were identified and selected for the study, within the domains socio-
demographic factors, functioning, co-morbidities and renal functioning. 
Socio-demographic factors
During baseline interviews, a research nurse collected information about the participants’ 
residency, income, level of education, body mass index and smoking habits.
Functioning
To assess cognitive function, the Mini-Mental State Examination (MMSE) was administered. 
Severe cognitive impairment was defined as a MMSE score below 19 points.24,25 The Geriat-
ric Depression Scale-15 (GDS-15) was performed to determine the presence of depressive 
symptoms. The presence of depressive symptoms was defined as a GDS-15 score above four 
points. The GDS-15 could only be administered in participants with an MMSE score above 19 
points.26,27 Disability in basic activities of daily living (ADL) was determined using the Gron-
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ingen Activity Restriction Scale (GARS)28 and defined as being unable to do any one of the 
following nine ADL: independently: walk inside, get out of bed, get into and out of a chair, 
use the toilet, wash hands and face, wash body, dress and undress, eat and drink, and make 
breakfast.29 The GARS-items were dichotomized. Participants were grouped into those who 
had no difficulty with GARS-items (score 1) and those who had difficulty or were unable to 
perform the GARS-items independently (score 2, 3 and 4). The total GARS score was calculated 
by adding the total scores of the nine items of the GARS and than dichotomized into score 9 
(independently) and scores > 9 (difficulty or unable to perform independently). All question-
naires were validated in Dutch. 
Co-morbidities
Information on participants’ medical history was obtained by standardised interviews with 
their treating general practitioner or elderly care physician and by examination of pharmacy 
records. We obtained clinical information on the presence of diabetes mellitus, stroke and 
cancer as well as information on unintentional loss of faeces and/or urine. Diagnosis of in-
continence was ascertained by the general practitioner or elderly care physician. For males, 
complaints of Lower Urinary Tract symptoms (LUTS) caused by benign prostatic hyperplasia 
(BPH) were measured with the International Prostate Symptom Score (IPSS). The IPSS is an 
eight-question written screening tool to rapidly diagnose BPH, track the symptoms of BPH 
and suggest management of the symptoms of BPH.30 The severity of urine incontinence was 
obtained by the PRAFAB-Questionnaire, which combines objective and subjective aspects 
of the severity of urinary incontinence.31-33 PRAFAB stands for Protection (the use of pads), 
Amount of urine loss, Frequency of urine loss, Adjustment of behaviour due to symptoms, and 
Body (or self ) image as a result of the stress urine loss symptoms.
Serum creatinine concentration was measured automatically according to the Jaffe meth-
od (Hitachi 747; Hitachi, Tokyo, Japan). Creatinine clearance was calculated from serum cre-
atinine concentration and body weight, using the Cockcroft-Gault formula.34 Low creatinine 
clearance was defined as a creatinine clearance below 30 mL/minute. For unknown disease, 
we measured C-reactive protein (CRP) levels with a fully automated Hitachi 911 analysis sys-
tem. CRP levels above 5 mg/L were considered elevated CRP levels.35 
data analyses
The incidence of UTI from age 86 years onwards was calculated during four years of follow-up 
(until age 90 years), using the life-table method. The number of first time UTI was assigned to 
the numerator and the observed person-years at risk were assigned to the denominator. The 
observed person-years at risk were counted from age 86 to the censor date (age 90 years), to 
date of death, or to date of first UTI. 
The association between predictive factors and the occurrence of UTI in participants from 
age 86 years onwards was investigated with Cox proportional hazards models. Those factors 
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predicting UTI in the univariate Cox regression analysis with a P-value < 0.10 were included in 
a multivariate Cox regression analysis. Since the GDS-15 could only be administered to par-
ticipants without cognitive impairment (MMSE  ≥ 19 points, n = 393), the variable ‘depressive 
symptoms’ was not included in the multivariate analysis. The relative contribution of the dif-
ferent predictive factors to the occurrence of UTI was determined by calculating the Popula-
tion Attributable Risk (PAR), which combines the relative risk and the prevalence of the differ-
ent predictive factors. Data analyses were performed using SPSS for Windows, version 16.0 
(SPSS Inc, Chicago, USA).
results
study population
Between September 1997 and September 1999, 705 participants were eligible for participa-
tion in the Leiden 85-plus Study. Ninety-two participants refused to participate and 14 par-
ticipants died before enrolment, resulting in a study population of 599 participants (response 
rate of 87%).36 For the present study, 72 participants for whom valid clinical information about 
UTI at age 86 was missing were excluded. Forty-eight participants died before the age of 86, 
resulting in a study population of 479 persons (response rate of 80.0% of the study popula-
tion).
Table 1 shows the baseline characteristics of the study population at age 86 years (n = 479). 
Two-thirds of the population was female and 22% of the participants were institutionalised 
in long-term care facilities. Restriction in ADL was registered in more than 59% of the par-
ticipants and 19% had an MMSE-score below 19 points. A total of 44% of the participants re-
ported urine incontinence and in almost 20% of the participants incontinence was diagnosed 
by the general practitioner or elderly care physician. A total of 15% of the participants had 
a history of UTI between the age of 85 and 86 years. Additional analysis showed that 8.3% 
of men and 18.3% of women had a history of UTI between the ages of 85 and 86 years (chi-
square 8.3; df = 1; P = 0.004). 
incidence of urinary tract infections
In four years of follow-up we observed 140 first episodes of UTI during 1,246 person-years (py) 
at risk. The overall incidence of UTI was 11.2 (95% CI 9.4-13.1) per 100 py at risk. Ninety-two 
participants had recurrent UTI (15.6% of the total population and 47.4% of the participants 
with UTIs). On average 6.5% (per year range 5.7-7.3) of all participants experienced two or 
more UTIs per year during follow-up, of which 45.6% (per year range 40.0-54.7) had more than 
one infection per year. A total of 246 participants died during follow-up, of whom seven par-
ticipants died from UTI according to CBS data. The incidence of UTI was 12.8 (95% CI 10.4-15.2) 
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per 100 py at risk for women and 7.8 (95% CI 5.1-10.6) per 100 py at risk for men. Women had a 
1.7-fold increased risk of developing UTI compared to men (HR 1.7 (95% CI 1.1-2.5); P = 0.012). 
Predictive factors of urinary tract infections
Table 1 shows the incidences of UTI in various groups for the studied predictive factors with 
their corresponding hazard ratios (HRs). The occurrence of UTI was univariately associated 
with (listed highest to lowest HR): a history of UTI between the ages of 85 and 86 years, un-
intentional loss of faeces, severe cognitive impairment (MMSE <19), institutionalisation, dis-
ability in daily living, self-reported urine incontinence, stroke, gender, education, and medical 
diagnosis of incontinence. UTIs were not associated with income, smoking, body mass index 
≥ 27, depressive symptoms, diabetes mellitus, BPH, cancer, severity of urine incontinence, pad 
use, creatinine clearance < 30 mL/minute and C-reactive protein > 5 mg/L. 
Additional analysis showed that all single items of the GARS (walk inside, get out of bed, 
get into and out of a chair, use the toilet, wash hands and face, wash body, dress and undress, 
eat and drink, and make breakfast) predicted the risk in developing UTI (Table 2).
After multivariate analysis, severe cognitive impairment (MMSE < 19), disability in daily liv-
ing, UTI between the ages of 85 and 86 years and self-reported urine incontinence remained 
independently and significantly predictive for the occurrence of UTI (Table 3). 
In both women and men, a UTI between the ages of 85 and 86 years was predictive for 
developing UTI from age 86 onwards (in women HR 3.8 (95% CI 2.5-5.6); P <0.001 and in men 
table 2. Risk of UTI from age 86 years onwards depending on disability (n = 479)
index group 
n (%)
incidence in
index group,
per 100 py 
(95% Ci)
incidence in 
reference group*,
per 100 py 
(95% Ci)
hr 
(95%Ci)
P-value
Going to the toilet 103 (21.5) 5.9 (4.5, 7.7) 2.6 (2.1, 3.2) 3.8 (2.7, 5.4) <0.001
Drinking and feeding oneself 44 (9.2) 6.0 (4.0, 9.0) 3.0 (2.5, 3.6) 3.5 (2.3, 5.6) <0.001
Washing hands and face 65 (13.6) 5.6 (4.0, 7.9) 2.9 (2.4, 3.6) 3.3 (2.2, 4.9) <0.001
Preparing breakfast 80 (16.7) 5.3 (3.8, 7.3) 2.9 (2.4, 3.5) 3.1 (2.1, 4.6) <0.001
Getting into and out of bed 128 (26.7) 5.1 (3.9, 6.6) 2.7 (2.2, 3.3) 2.6 (1.9, 3.7) <0.001
Getting around the house 133 (27.8) 4.6 (3.5, 6.0) 2.8 (2.2, 3.4) 2.4 (1.7, 3.3) <0.001
Washing whole body 204 (42.6) 4.3 (3.5, 5.4) 2.5 (2.0, 3.3) 2.3 (1.7, 3.3) <0.001
Dressing oneself 183 (38.2) 4.3 (3.4, 5.4) 2.7 (2.1, 3.4) 2.1 (1.5, 3.0) <0.001
Standing up from a chair 147 (30.7) 4.3 (3.3, 5.6) 2.9 (2.3, 3.5) 2.0 (1.4, 2.8) <0.001
py = person-years; CI = confidence interval; HR = hazard ratio; 
*Definition of reference groups: no disability going to the toilet , no disability drinking and feeding oneself, no disability 
washing hands and face, no disability preparing breakfast, no disability in getting into and out of bed, no disability in getting 
around the house, no disability washing whole body, no disability dressing oneself, no disability standing up from chair.
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HR 4.4 (95% CI 1.8-10.8); P = 0.001). Further stratified analysis showed that severe cognitive 
impairment (MMSE < 19) was associated with a three times higher risk in developing UTI in 
women (HR 3.0 (95% CI 2.0-4.5); P <0.001), but not in men (HR 1.5 (95% CI 0.6-3.9); P = 0.41). 
Moreover, stroke showed significantly higher risk for developing UTI in women (HR 2.0 (95% 
CI 1.2-3.4); P = 0.005), but not in men (HR 1.6 (95% CI 0.6-4.2); P = 0.346). Also higher risk was 
found for CRP > 5 mg/l in women (HR 1.5 (95% CI 1.0-2.2); P = 0.049), but not in men (HR 0.8 
(95% CI 0.4-1.8); P = 0.633). Stratification for living situation (independently or long-term care 
facility) shows no differences in predictive factors for UTI (Table 4). 
Participants with UTI between the ages of 85 and 86 years had an increased risk of devel-
oping UTI during follow-up compared to participants without an episode of UTI between the 
ages of 85 and 86 years (Figure 1 and Table 1; HR 4.1 (95% CI 2.9-5.9)). The risk of a recurrent 
UTI was greatest within the first year of follow-up (HR: 6.8 (95% CI 4.1-11.1), HR second to 
fourth year: 1.8 (95% CI 0.9-3.6)). 
Additional analysis showed that among participants without an UTI between the ages of 
85 and 86 years, female gender and stroke were predictors of developing UTI (HR 1.5 (95% CI 
1.0-2.4); P = 0.059 for gender and HR 2.0 (95% CI 1.2-3.2); P = 0.011 for stroke, respectively). No 
further differences in hazard ratios were observed for the other potentially predictive factors 
between participants who had had a UTI between the ages of 85 and 86 years and partici-
pants who had not had an UTI. 
table 3. Factors predictive for increased risk of developing UTI after age of 86 years onwards by multivariate Cox regression 
analysis and Population Attributable Risk (PAR) of the occurrence of UTI (n = 479)
n hr (95%Ci) PAr (%)
functioning
Severe cognitive impairment (MMSE < 19) 88 1.9 (1.3, 2.9) 19.6
Disability in daily living† 275 1.7 (1.1, 2.5) 43.8
Co-morbidities
UTI between the ages of 85 and 86 years 68 3.4 (2.4, 5.0) 24.1
Self-reported urine incontinence 231 1.5 (1.0, 2.1) 33.0
Variables in multivariate Cox regression model: gender, institutionalisation, education, severe cognitive impairment  
(MMSE < 19), disability in daily living, UTI between the ages of 85 and 86 years, stroke, unintentional loss of faeces, self-
reported urine incontinence and medical diagnosis urine incontinence.
CI = confidence interval; HR = hazard ratio; MMSE = Mini-Mental State Examination; UTI = urinary tract infection
†Disability in daily living = unable to do any one of the nine basic activities of daily living independently, according to the 
Groningen Activity Restriction Scale.
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table 4. Predictive factors for UTI stratified for living situation by univariate Cox regression analysis after the age of 86 years
independently (n = 372) long-term care facility (n = 107)
n hr (95%Ci) P-value n hr (95%Ci) P-value
socio-demographic factors
Female 242 1.4 (0.9, 2.3) 0.127 80 2.1 (0.9, 4.9) 0.098
Low income 170 1.0 (0.7, 1.5) 0.914 68 0.9 (0.5, 1.6) 0.650
Primary school only 221 1.2 (0.8, 1.9) 0.452 75 2.3 (1.1, 4.9) 0.036
Smoking (current) 55 1.1 (0.6, 1.9) 0.817 15 1.4 (0.6, 3.1) 0.443
Body Mass Index ≥ 27 171 1.2 (0.8, 1.8) 0.329 41 0.9 (0.4, 1.7) 0.655
functioning
Severe cognitive impairment
(MMSE < 19)
36 1.9 (1.1, 3.4) 0.030 54 2.3 (1.2, 4.4) 0.009
Depressive symptoms (GDS-15 > 4) 46 1.2 (0.6, 2.2) 0.578 12 0.2 (0.0, 1.7) 0.146
Disability in daily living† 191 1.9 (1.3, 2.9) 0.002 92 3.6 (1.1, 11.7) 0.033
Co-morbidities
Diabetes mellitus 53 0.8 (0.4, 1.5) 0.536 23 1.1 (0.5, 2.6) 0.759
Stroke 31 1.4 (0.8, 2.8) 0.269 29 1.6 (0.9, 3.1) 0.143
Cancer 80 1.1 (0.6, 1.8) 0.845 17 1.0 (0.4, 2.4) 0.963
Benign Prostatic Hyperplasia
(IPSS score ≥ 8)
49 1.3 (0.6, 2.9) 0.521 4 NA NA
UTI between the ages of 85 and 86 years 41 3.3 (2.1, 5.3) <0.001 31 4.1 (2.2, 7.5) <0.001
Unintentional loss of faeces 35 2.7 (1.6, 4.8) <0.001 30 2.5 (1.3, 4.6) 0.004
Self-reported urine incontinence 143 1.7 (1.2, 2.6) 0.007 69 1.9 (0.9, 4.0) 0.071
Medical diagnosis incontinence 69 1.3 (0.8, 2.2) 0.260 26 1.7 (0.9, 3.4) 0.110
PRAFAB score ≥ 11 76 0.7 (0.3, 1.7) 0.462 24 NA NA
PRAFAB: Pad use 69 1.0 (0.4, 2.2) 0.949 22 1.9 (0.3, 15.1) 0.530
Creatinine clearance < 30 mL/minute 29 0.8 (0.4, 1.6) 0.487 14 1.8 (0.5, 5.8) 0.337
CRP > 5 mg/L 116 1.2 (0.8, 1.8) 0.425 43 1.1 (0.6, 2.1) 0.664
HR = hazard ratio; CI = confidence interval; CRP = C-reactive protein; GDS-15 = ‘Geriatric Depression Scale’ with 15 items 
(only administered to participants with MMSE ≥19); IPSS = ‘International Prostate Symptom Score’ (only administered to 
male participants with MMSE-score ≥ 19); MMSE = Mini-Mental State Examination; PRAFAB = 5-item questionnaire score 
incontinence (only administered to participants with MMSE-score ≥ 19); py = person-years; UTI = urinary tract infection.
†Disability in daily living = unable to do any one of the nine basic activities of daily living independently, according to the 
Groningen Activity Restriction Scale 
NA = not applicable
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Population Attributable risk
Table 3 presents the relative contribution of the various predictive factors to the occurrence 
of UTI from age 86 years onwards, expressed by the Population Attributable Risk (PAR) of each 
variable that was shown to be predictive of UTI in the multivariate analysis. The highest PARs 
for the development of UTI were found for disability in daily living (44%), self-reported incon-
tinence (33%), history of UTI between the age of 85 and 86 years (24%) and severe cognitive 
impairment (20%). After multivariate analysis gender, institutionalisation, education, stroke, 
unintentional loss of faeces and medical diagnosis urine incontinence were not predictive 
any more for UTI. 
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UTI 72     50 43                  38         30
No UTI 407     370 319                  277         250
figure 1. Cumulative incidence of UTI from age 86 onwards depending on history of UTI between the age of 85 and 86 years. 
Black line: participants with episode of UTI between the ages of 85 and 86 years (n=72). Dotted line: participants without 
episode of UTI between the ages of 85 and 86 years (n=407).
Log rank: chi-square 72.9; df =1; P <0.001
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disCussion
In this population-based prospective follow-up study among the oldest old, the incidence of 
UTI was 11.2 per 100 person years at risk. Severe cognitive impairment, disability in daily liv-
ing, history of UTI between the age of 85 and 86 years and self-reported urine incontinence 
were among the strongest predictors for developing UTI from age 86 years onwards. The Pop-
ulation Attributable Risk was highest for disability in daily living (44%). 
As in other studies, we found females to have a greater risk of developing UTI than men. 
However, in the multivariate analysis gender was no longer a predictor of UTI. Possibly, in old 
age, other predictors play a greater role in predicting UTI than gender per se. In spite of the 
differences between older persons living independently and older persons living in long-term 
care facilities; we found the same predictive factors for UTI from the age 86 years onwards in 
both populations. 
It is well known that patients with a history of UTI have a higher rate of UTI than those with-
out a history of UTI.1,20 In our study a history of UTI between the ages of 85 and 86 years was 
a strong predictor of recurrent UTI from the age of 86 years onwards. Besides a history of UTI 
between the age of 85 and 86 years, our study showed that disability in daily living and severe 
cognitive impairment, both factors reflecting declined functional status, were also predictors 
of UTI. These findings are in line with other studies.16,19,20 Since 19% of our population-based 
sample was severely cognitively impaired and almost 60% had disability in daily activities, 
declined functional status greatly contributes to the occurrence of UTI in the general oldest 
old population. 
Although diabetes mellitus has been shown to be associated with greater predisposition 
to UTI in other study populations,17,18,37-39 we did not find any association between diabetes 
mellitus and UTI in our study population. Perhaps differences in age, type of diabetes and 
definition of UTI explain these contradictory findings. On the other hand, previous studies 
showed that diabetes was no longer associated with cognitive decline and the incidence of 
lower respiratory tract infections at old age, indicating that the clinical impact of diabetes is 
possibly diminished in old age.40,41
The present study is a unique population-based sample of participants aged 86 years and 
over, with extensive baseline measurement and almost complete follow-up for morbidity and 
mortality. To our knowledge, we are the first to examine the incidence and predictive factors 
of UTI in a large group of unselected very old individuals in a population-based setting. It is 
important to study predictive factors of UTI in old age specifically, because they are the fast-
est growing part of the general population and the incidence of UTI increases with age.3-5 The 
fact that we only studied 86-year-olds could also be considered a limitation of our study. Since 
bladder structure and function, and the immune system have been shown to change with 
age,3 our results may not be generalized to younger elderly. Another limitation of our study 
might be that UTIs were diagnosed during clinical practice, not diagnosed by standardised 
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diagnostic study procedures. In our study, however, all UTIs were diagnosed by general prac-
titioners and elderly care physicians based on signs and symptoms and urine analysis. This 
procedure reflects usual care and enables generalisation of our results to daily care for the 
oldest old.
It is generally known that symptomatic UTI is over-diagnosed in elderly populations given 
the high prevalence of asymptomatic bacteriuria,5 especially in long-term care facilities with 
a prevalence of 25 to 50%.22 Also difficulties in communication, chronic genitourinary symp-
toms, and the high frequency of positive urine cultures, make ascertainment of symptomatic 
UTI problematic for the functionally impaired elderly.22 Also urine cultures are often contami-
nated and the lack of existence of specific markers of infectious bladder inflammation makes 
it difficult to diagnose UTI in impaired elderly. In our study, we found an UTI incidence of 11.2 
per 100 person years at risk for persons aged 86 years and over. This may be an overestimation 
due to the presence of bacteriuria. However, the incidence found in this study is comparable 
with data from the Dutch national GP registration (11.7 for men and 29.4 for women aged 85 
years and over)4 and the fact participants actively visited their treating physician with UTI like 
symptoms. 
Further, it is known that long-term catheterization is a strong risk factor for UTI and bacteri-
uria in institutionalized older persons.10 Unfortunately, we did not have any information about 
long-term catheterization in our study population and could not report on the predicting 
effect. These is a limitation of our study, but we believe that this may not have affected the 
results of our study much, since in Dutch nursing homes there is a policy to avoid the use of 
catheters in situ and it has been so for many years.42
ConClusions
In older populations, UTIs account for nearly 25% of all infections.1,2 As UTIs are associated with 
serious negative outcomes, it is important to consider preventive strategies for UTI in older 
individuals. Our study showed four important predictors for UTI: severe cognitive impairment, 
disability in ADL, history of UTI between the ages of 85 and 86 years, and self-reported urine 
incontinence. Remarkably, none of these predictors appear to be modifiable. However, these 
predictors could still be used in the development of a clinical prediction rule to select for 
whom apply preventive strategies. Prophylaxis with low-dose, long-term antibiotics,12,13 oes-
trogens14 and cranberry products12,15 are potential strategies to prevent UTI, but so far none of 
these strategies have been proven to prevent UTI in the very old. Selection of high risk oldest 
old is a crucial first step in successful prevention of UTI. Before these preventive strategies may 
be introduced in the oldest old, their effects and side effects have to be studied in randomised 
intervention studies.
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ABstrACt
objectives To determine whether cranberry capsules prevent urinary tract infection (UTI) 
in long-term care facility (LTCF) residents.
design Double-blind randomized placebo-controlled multicenter trial.
setting Long-term care facilities (LTCFs).
Participants LTCF residents (N = 928; 703 women, median age 84).
Measurements Cranberry and placebo capsules were taken twice daily for 12 
months. Participants were stratified according to UTI risk (risk factors included long-term 
catheterization, diabetes mellitus, ≥ 1 UTI in preceding year). Main outcomes were incidence 
of UTI according to a clinical definition and a strict definition. 
results In participants with high UTI risk at baseline (n = 516), the incidence of clinically 
defined UTI was lower with cranberry capsules than with placebo (62.8 vs 84.8 per 100 
person-years at risk, P = 0.04); the treatment effect was 0.74 (95% confidence interval 
(CI) = 0.57-0.97). For the strict definition, the treatment effect was 1.02 (95% CI = 0.68-1.55). 
No difference in UTI incidence between cranberry and placebo was found in participants 
with low UTI risk (n = 412).
Conclusions In LTCF residents with high UTI risk at baseline, taking cranberry capsules 
twice daily reduces the incidence of clinically defined UTI, although it does not reduce the 
incidence of strictly defined UTI. No difference in incidence of UTI was found in residents 
with low UTI risk. 
Key words Geriatrics, long-term care facility, urinary tract infection, prevention, cranberry
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introduCtion
Urinary tract infection (UTI) is a common bacterial infection in residents of long-term care fa-
cilities (LTCF),1,2 accounting for nearly 25% of all infections.3,4 UTI not only causes several days 
of illness, but may have more-severe consequences such as delirium, dehydration, urosepsis, 
hospitalization, or even death.5,6
Interventions to prevent UTI could reduce these severe consequences,7 but there are no 
evidence-based interventions that decrease UTI in institutionalized populations.1 The use of 
prophylactic antibiotics is currently controversial because of side-effects and antibiotic resis-
tance.8,9 Prophylaxis with cranberry is a potential prevention strategy.10,11 Cranberries contain 
proanthocyanidins (PACs), which are stable phenolic compounds with anti-adhesion activ-
ity against Escherichia coli.12-14 In vitro, antibacterial activity of concentrated cranberry juice 
against other pathogens such Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella 
pneumoniae, and Proteus mirabilis has also been demonstrated.15,16
There is aggregated evidence that cranberry juice may lead to a decrease in the incidence 
of symptomatic UTIs over a 12-month period, particularly in women with recurrent UTIs.17,18 
Another recent systematic review indicates that cranberry-containing products are associated 
with a protective effect against UTI in different subgroups, albeit with heterogeneity across 
the included trials.19 A recent study in children without urological abnormalities showed a 
65% reduction of UTI with the use of cranberry.20
Two studies reported that cranberry juice may be protective in subgroups of older 
adults,21,22 but the effectiveness of cranberry capsules in the protection against UTI in vulner-
able older  persons in LTCFs has not been studied.
The present study assessed the effectiveness of cranberry capsules in preventing UTI in 
vulnerable older persons living in LTCFs. Research in an institutionalized population is chal-
lenging, and clinical manifestations of UTI may be subtle. 23-25 To be relevant for clinical prac-
tice and science, a clinical definition according to international guidelines for LTCF residents 
and a strict definition according to scientific criteria were both used.
Methods
design
This was a double-blind randomized placebo-controlled multicenter trial in two strata, based 
on baseline UTI risk. Twenty-one LTCF organizations from the University Nursing Home Re-
search Network in South Holland, the Netherlands, participated.
The medical ethics committee of the Leiden University Medical Center approved the study. 
Written informed consent was obtained from all participants. A guardian provided written 
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consent for participants incapable of giving informed consent because of cognitive impair-
ment.
study participants
LTCF residents aged 65 and older were included. Exclusion criteria were use of coumarin and 
a life expectancy of 1 month or less. Coumarin users were excluded because of a possible in-
teraction between coumarin and cranberry, leading to higher international normalized ratios 
and bleeding.26-28
After informed consent and before randomization, medical records were studied to stratify 
participants according to baseline UTI risk. Participants with long-term catheterization (> 1 
month), diabetes mellitus, or at least one UTI in the preceding year were considered to be at 
high UTI risk.
Within two strata of UTI risk, participants were randomized into the cranberry or placebo 
group. Block randomization (blocks of 6) was used, stratified for risk profile and ability to give 
informed consent, generated using a computer random number generator. Participants, fam-
ily, nursing staff, physicians, pharmacists, and research nurses were blinded to treatment, and 
the random numbers were put in sealed envelopes so the research nurse could allocate to the 
treatment group (cranberry or placebo) directly on the ward. Only the supplier of the capsules 
knew the codes given to the capsules (cranberry or placebo).
intervention
Participants were randomly assigned to take cranberry or placebo capsules twice daily for 12 
months. Participants already using a cranberry supplement stopped using their own cran-
berry products before randomization and changed to the study capsule at baseline. The 
cranberry capsules contain 500 mg of the product, with 1.8% proanthocyanidins (9 mg). The 
placebo was indistinguishable in color, taste, and appearance, consisting of cellulose micro-
crystal colored red with azorubin.
The physician prescribed the coded capsules, and the pharmacist added them to the drug-
dispensing systems. Nurses distributed the capsules and recorded whether the participant 
took them on a drug kardex. Adherence was measured over 1 month by counting all capsules 
that the participants took during the fifth month of intervention and comparing that with the 
prescribed number of capsules.
outcome measures
The primary outcome was incidence of UTI. There is no criterion standard in diagnosing UTI 
in LTCF residents. Most clinical criteria to ascertain UTI are based on consensus.29-31 A recent 
study showed that micturition-related signs and symptoms are predictive of UTI.32
Because of the absence of a criterion standard in the study population, this study used a 
clinical definition and a strict UTI definition. The clinical definition of UTI is a broad and practi-
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cal definition following clinical practice guidelines for LTCF residents.24,25 This clinical defini-
tion of UTI is based on the presence of a minimum of one of the following characteristics: 
specific and nonspecific micturition-related symptoms and signs, a positive test (nitrite test, 
leukocyte esterase test, dipslide, or culture), antibiotic treatment for UTI, or UTI reported in 
the medical record. 
Specific symptoms and signs are pain before, during, or after micturition; increased fre-
quency of micturition; pain in abdomen; hematuria; foul smell; and signs of common sickness 
(fever > 37.9°C or 1.5°C above baseline temperature, chills, nausea, vomiting). Nonspecific 
symptoms are anorexia, fatigue and reduced mobility, and signs of delirium (e.g., confusion, 
deterioration in mental or functional status).
The strict UTI definition is based on a scientific approach, including the presence of mic-
turition-related symptoms and signs confirmed with a positive dipslide or culture. A urine 
dipslide or culture was considered to be positive when there were 105 CFU/mL or more bacte-
ria, with no more than two species of organisms present.
The treating physicians diagnosed the UTI and reported the presence of UTI in the medi-
cal record. For this study, they reported the needed study information on a prestructured 
case report form, including presence of specific and nonspecific micturition-related signs and 
symptoms, kind of testing and results, and antibiotic treatment. Secondary outcomes were 
incidence of recurrent UTI, hospitalization, and mortality.
In a companion cost-effectiveness article, whether the effectiveness of cranberry capsule 
use is attained at reasonable costs was investigated.33
At 6 and 12 months, a research nurse visited all participants in their LTCF to check their 
medical records for the occurrence of UTIs and to verify that all UTIs were collected during the 
study period. Side effects and reasons for withdrawal from the study were registered.
Additional measurements at baseline
A research nurse interviewed all participants at baseline in their LTCF, where face-to-face in-
terviews were conducted. If participants were not able to answer, their responsible nurse was 
interviewed. Information on participant sociodemographic characteristics and medical his-
tory were obtained at baseline. Care dependency was assessed using the Care Dependency 
Scale (CDS),34 which measures 15 items of basic care needs on an aggregate scale from 15 to 
75.
sample size
Sample size was based on an expected incidence of 44 first UTIs per 100 residents per year in 
the placebo group. To demonstrate a 40% reduction in incidence of UTI with the use of cran-
berries,22 500 residents needed to be included in each stratum (2 strata of 2 groups of 250), 
1,000 residents in total (dropout rate 10%, alpha 0.05, power 80%).
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statistical analysis
Differences in baseline characteristics between treatment groups were compared using the 
Student t-test for continuous variables and chi-square for categorical variables. The incidence 
of UTI was calculated using the life-table method. The number of first UTIs was assigned to the 
numerator and the number of observed person-years at risk was assigned to the denominator. 
The observed person-years at risk were counted from randomization to end of study, to date 
of death, or to date of first UTI. The cumulative incidence of UTI for cranberry and placebo 
was calculated accounting for mortality as competing risk.35 The difference in the cumulative 
incidence of UTI in residents between cranberry and placebo was tested using the log-rank 
test. The treatment effect of cranberry with respect to placebo was investigated using Cox 
proportional hazards models, expressed as hazard ratios (HRs).
The number needed to treat (NNT) was calculated over 1 year of follow-up, based on the 
difference in proportion of being event free in the placebo and cranberry group.36,37 The dif-
ference in NNT between treatment groups was tested using a z-test; P = 0.05 was considered 
significant.
To investigate possible heterogeneity in UTI rates between individuals, a gamma-frailty 
model was fitted,38 a random effect model for time-to-event data in which the random ef-
fect (frailty) has a multiplicative effect on baseline hazard function. Analyses were performed 
based on intention to treat using SPSS for Windows version 17.0 (SPSS Inc., Chicago, IL) and R 
version 2.13.0 (R Foundation for Statistical Computing, Vienna, Austria).
results
Between November 2008 and August 2009, all 2,086 eligible residents were invited to partici-
pate in a letter, and then a research nurse orally invited them. The study stopped in June 2011. 
Twenty-seven of the 955 residents who gave written informed consent died before random-
ization, resulting in a study population of 928 participants (Figure 1). A nonresponder analysis 
for giving informed consent showed no difference between nonresponders and responders in 
age, sex, or UTI risk profile. None of the participants had end-stage renal disease.
Four hundred twelve low-UTI-risk and 516 high-UTI risk-participants were included. There 
were no baseline differences within the UTI risk groups between the cranberry and placebo 
groups (Table 1). Mean capsule intake was 97% (95% confidence interval (CI) = 96.6-97.6%) 
and was similar between the randomization groups and between the risk groups.
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incidence of uti
In the high-UTI-risk group, the curve of cumulative incidence of clinically defined UTI showed 
a positive treatment effect from 2 months of follow-up onward (P = 0.03). No such effect was 
found for strictly defined UTI (P = 0.91). There was no difference between cranberry and pla-
cebo in the low-UTI-risk group (Figure 2).
Low UTI-risk group (cranberry n=205; placebo n=207)
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High UTI-risk group (cranberry n=253; placebo n=263)
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figure 2.  Cumulative incidence of urinary tract infection (UTI) within 1 year of follow-up depending on treatment (cranberry 
or placebo) stratified for those at low and high UTI-risk, accounting for mortality as competing risk.
Solid line: cranberry group; dotted line: placebo group. Clinical definition: symptom or positive testing (nitrite test, leukocyte 
esterase test, dipslide or culture) or antibiotic treatment or UTI reported in the medical record. Strict definition: symptom and 
positive dipslide or culture.
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In the high-UTI-risk group, the incidence of UTI according to the clinical definition was 62.8 
per 100 person-years at risk (95% CI = 50.3-75.2) for cranberry and 84.8 per 100 person-years 
at risk (95% CI = 70.0-99.7) for placebo (P = 0.04). The treatment effect in those at high UTI risk 
was 0.74 (95% CI = 0.57-0.97). The incidence for UTI following the strict definition was not dif-
ferent in those using cranberry and placebo. The treatment effect was 1.02 (95% CI = 0.68-1.55; 
Table 2). A subanalysis in participants without long-term catheters in the high-UTI-risk group 
(n = 420) showed a larger treatment effect of cranberry capsules than of placebo for clinically 
defined UTI (Table 2). According to the clinical definition, five high-risk residents need to be 
treated with cranberry for 1 year to prevent one resident free of UTI for 1 year (P = 0.01).
In the low-UTI-risk group, the incidence of UTI according to the clinical definition was 40.3 
per 100 person-years at risk (95% CI = 30.0-50.5) for cranberry and 33.4 per 100 person-years 
at risk (95% CI = 24.2-42.5) for placebo (P = 0.30).
recurrent uti
In a gamma-frailty model (a random effect model) using  all recurrent clinical UTIs, cranberry 
did not significantly reduce the UTI rate in the high-UTI-risk group (HR = 0.92, 95% CI = 0.71-
1.17, frailty variance 0.62, P < 0.001). In the low-UTI-risk group, the HR of cranberry versus 
placebo was 1.14 (95% CI = 0.78-1.68, frailty variance 1.50, P < 0.001).
hospitalization and mortality
Five participants (0.5%), all from the high-UTI-risk group, were hospitalized during follow-
up for UTI, with no difference between cranberry and placebo (P = 0.62). In the low-UTI-risk 
group, 114 (27.7%) participants died during follow-up, of whom three died from UTI (cran-
berry vs placebo P = 0.56). In the high-UTI-risk group, 181 participants (35.1%) died during 
follow-up, of whom 14 (7.7%) died from UTI, with no difference between cranberry and pla-
cebo (7 vs 7 P = 0.91).
disCussion
This double-blind randomized placebo-controlled multicenter trial investigated the effective-
ness of cranberry capsules to prevent UTI in older LTCF residents. In participants with high UTI 
risk, twice-daily intake of cranberry capsules resulted in a 26% lower incidence of clinically 
defined UTI than placebo, but no difference was found in UTI incidence of strictly defined UTI. 
In residents with low UTI risk, twice-daily intake of cranberry capsules did not result in a lower 
incidence of UTI than with placebo.
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effectiveness
A systematic review showed that cranberry-containing products were associated with a pro-
tective effect against UTI in certain populations.19 A Cochrane review reported a UTI reduction 
of 35% (95% CI = 10-54%).17 In the recent update of this Cochrane review in 2012, the au-
thors performed a meta-analysis based on two studies evaluating cranberry in elderly adults 
(N = 413).18 Cranberry did not significantly reduce UTI in this population (risk ratio = 0.75, 
95% CI = 0.39-1.44).18 In contrast with this last review, the current study found a positive ef-
fect of treatment with cranberry capsules on the incidence of clinically diagnosed UTI in 516 
older persons with high UTI risk. A possible explanation for this difference could be the prod-
uct used (juice vs capsules), study population (hospitalized vs institutionalized), and sample 
size. Another study comparing cranberry with low-dose trimethoprim (follow-up 6 months) 
showed no difference between cranberry and low-dose antibiotics but did not include a pla-
cebo arm.39 
It could have been expected that the beneficial effect of cranberry capsules would be fairly 
prompt after starting treatment, but the current study showed a beneficial effect of cranberry 
capsules in the high-UTI-risk group starting from 2 months of treatment on for clinically de-
fined UTI. This was shown in an earlier study that found a reduction that started between 1 
and 2 months after initiating cranberry juice and remained stable throughout the 6 months 
of follow-up.21 Cranberries with PAC were expected to have an effect by different mechanisms, 
because they influence the adhesive capacity of fimbriae of bacteria and build a biofilm on 
the surface, preventing adhesion. Nevertheless, bacteria could be persistent (chronic bacteri-
uria), and the types of bacteria could vary over time. So cranberry protects against UTI, but it 
takes some time to have an effect.
Because the effect of preventive care depends on the incidence of the disease, a pre-
planned stratification was made at baseline on baseline UTI risk. Based on the literature, LTCF 
residents with diabetes mellitus,40-42 long-term catheterization,24,43,44 or UTI in the preceding 
year3,42,45,46 were considered to be at high risk. Although a group of LTCF residents with a high 
incidence were selected using these criteria, it might be that other criteria would have se-
lected a group with even higher risks or more preventable UTIs.
strengths and limitations
This is the first large study of the effectiveness of cranberry capsules in preventing UTI in LTCF 
residents. These residents represent a vulnerable older population, with a median age of 85 
and older, severely dependent on care, high infection rates, high levels of comorbidity, and 
1-year mortality of 35%,47 a population in which clinical manifestations of UTI may be subtle.23
The current study was performed in Dutch LTCFs , intramural care settings where elderly 
care physicians provided medical care.48-50 Medication prescription and distribution are well 
organized. The study capsules were added to the existing drug-dispensing system. Medica-
tion distribution by nurses is routine in Dutch LTCFs, and participants rarely missed taking 
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any capsule, which was reflected in a high adherence rate, although adherence was assessed 
only in the fifth month, which might not be generalizable to the other months. This high and 
similar level of adherence in both treatment groups also suggests that capsules were well tol-
erated, side-effects were negligible, and blinding remained adequate during the study.
A technical assessment of blinding was not performed, although the research nurses did 
not receive information about deblinding during the study visits. In addition, the distribution 
and adherence of participants in the cranberry and placebo groups were similar.
The clinical definition for UTI is based on a broad definition of UTI (symptoms and signs, 
positive test, antibiotic treatment, or reported in the medical record) and relies on the clinical 
judgment of the elderly care physician, in accordance with international clinical guidelines for 
UTIs in LTCFs.24,25 Although this UTI definition is different from the strict definition, it reflects 
clinical care in LTCFs and adds knowledge to practice guidelines to assist physicians in making 
decisions.
The strict definition of UTI is based on a scientific approach, including micturition-related 
symptoms and signs confirmed according to a positive culture or dipslide, and could be used 
for comparisons with studies in other populations but is difficult to generalize to clinical prac-
tice in LTCFs. It is generally accepted that diagnosing UTI in vulnerable older persons, especial-
ly in long-term care, is complicated. A recent study in nursing home residents with advanced 
dementia showed that symptoms and signs of UTI are frequently not present in older persons 
with dementia.51 In the current study, for example, most participants had dementia (76%) or 
incontinence (64%). Therefore, a clean catch urine sample for culturing is often not available, 
making it impossible to diagnose UTI according to the strictest criteria.52 The current study 
was doubleblinded, so the randomization itself cannot have influenced the clinical definition. 
Despite the large study sample, no treatment effect was shown in those at high UTI risk us-
ing the strict definition. The study may have been slightly underpowered for the rarer strictly 
defined UTIs.
The optimum dosage of cranberries is not clear, and a well-designed dose-finding study 
is needed. An in vitro study suggests that the administration of 72 mg of PAC daily may offer 
some protection against bacterial adhesion in the bladder.53 The daily use of 18 mg of PAC 
(two capsules) in this study may not have been high enough.
These results are not automatically generalizable to vulnerable older persons living at 
home. Differences not only in vulnerability and infection rates, but also in adherence and 
hospitalization rates were expected.
ConClusions
In LTCF residents with high UTI risk, taking cranberry capsules twice daily results in a 26% 
lower incidence of clinically defined UTI than with placebo, although no difference was found 
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in UTI incidence according to a strict definition. Cranberry capsules may offer an opportunity 
to decrease the incidence of this common infection in high-UTI-risk LTCF residents by using a 
well-tolerated treatment.
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ABstrACt
objectives To investigate whether the preventive use of cranberry capsules in long-term 
care facility (LTCF) residents is cost-effective depending on urinary tract infection (UTI) risk.
design Economic evaluation with a randomized controlled trial.
setting Long-term care facilities.
Participants LTCF residents (N = 928, 703 female, median age 84), stratified according to 
UTI risk.
Measurements UTI incidence (clinically or strictly defined), survival, quality of life, quality-
adjusted life years (QALYs), and costs.
results In the weeks after a clinical UTI, participants showed a significant but moderate 
deterioration in quality of life, survival, care dependency, and costs. In high-UTI-risk 
participants, cranberry costs were estimated at €439 per year (1.00 euro = 1.37 U.S. 
dollar), which is €3,800 per prevented clinically defined UTI (95% confidence interval = 
€1,300-infinity). Using the strict UTI definition, the use of cranberry increased costs without 
preventing UTIs. Taking cranberry capsules had a 22% probability of being cost-effective 
compared with placebo (at a willingness to pay of €40,000 per QALY). In low-UTI-risk 
participants, use of cranberry capsules was only 3% likely to be cost-effective. 
Conclusion In high-UTI-risk residents, taking cranberry capsules may be effective in 
preventing UTIs but is not likely to be cost-effective in the investigated dosage, frequency, 
and setting. In low-UTI-risk LTCF residents, taking cranberry capsules twice daily is neither 
effective nor cost-effective.
Key words Economic evaluation, geriatrics, long-term care facility, urinary tract infection, 
prevention, cranberry
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introduCtion
Urinary tract infection (UTI) is a common bacterial infection in residents of long-term care 
facilities (LTCFs).1-4 The effectiveness of the use of cranberry capsules to prevent UTIs was 
assessed in a randomized controlled trial.5 In residents with high UTI risk, taking cranberry 
capsules twice daily reduced the incidence of clinically defined UTI by 26%. No reduction 
was found for strictly defined UTI or in residents with low UTI risk. The current brief report 
investigates the effect of UTI on health and costs and whether the preventive use of cranberry 
capsules in LTCFs is cost-effective.
Methods
This economic evaluation was part of a double-blind randomized placebo-controlled multi-
center trial.5 Residents from LTCFs (N = 928, median age 84, 703 female) were randomized to 
receive cranberry or placebo capsules twice daily for 12 months. The cranberry capsules con-
tained 500 mg of the product with 1.8% proanthocyanidins (9 mg). Participants were stratified 
according to UTI risk (including long-term catheterization, diabetes mellitus,  ≥ 1 UTIs in the 
preceding year). Main outcomes of the trial were incidence of UTI according to a clinical defi-
nition (following clinical practice guidelines for residents in LTCFs) and a strict definition (with 
confirmation by a positive dipslide or culture).5
Cost-effectiveness and cost-utility analysis
The economic evaluation consisted of a cost-effectiveness analysis (CEA) from a narrow per-
spective and a cost-utility analysis (CUA) from a lifelong societal perspective for high- and for 
low-UTI-risk participants.
The CEA from a narrow perspective was based directly on the trial data during follow-up, to 
prevent modeling assumptions. Effectiveness was measured according to the number of clini-
cally defined and strictly defined UTIs (first and recurrent). Costs included only cranberry use.
The CUA was performed from a lifelong societal perspective. Costs, survival and quality-
adjusted life years (QALYs) were estimated using a non-Markovian state-transition model, with 
parameters estimated from the trial data. In this model, the cranberry and placebo groups dif-
fered in their clinically defined UTI infection rate but not in the consequences per UTI. Thus, it 
was implicitly assumed that prevented UTIs are comparable with non-prevented UTIs and that 
cranberry use has no relevant effects other than cranberry costs and UTI prevention. These 
modeling assumptions were made beforehand because it was clear that the study would have 
insufficient power for a direct randomized economic comparison.
Chapter 6
90
In the CUA model (Figure 1), participant time was categorized into five model states: during 
the initial 2 months and before the first UTI, after the initial 2 months and before the first UTI, 
during the first month after the first UTI, after the first month after the first UTI, and death.
uti infection rate and mortality
Three separate annual UTI infection rates were estimated in a combined Poisson regression 
analysis. Infection rates in the cranberry and placebo groups were different after the first 2 
months and before the first UTI (State 2). No effect of cranberry use was seen in the initial 
2 months (State 1) or after the first UTI (States 3 and 4). Occurrence of a first UTI was associ-
ated with greater mortality during the subsequent month (State 3) and after the subsequent 
month (State 4). Annual mortality was estimated in a combined Poisson regression analysis.
utilities
Utilities represent the valuation of the quality of life of the participants on a scale anchored 
at 1 (perfect health) and 0 (as bad as being dead). Utility was measured using the EQ-5D clas-
sification system, which is a brief questionnaire with five domains (mobility, self-care, usual 
activities, pain and discomfort, and anxiety and depression), each with three levels (no, some, 
or extreme problems).6 Utility values were assigned to the EQ-5D using the Dutch tariff.7
Valuations were also obtained using a visual analog scale (VAS) ranging from 100 (perfect 
health) to 0 (worst imaginable health), which was transformed to a utility scale using a power 
transformation.8 EQ-5D and VAS measurements were obtained from the participants (11%) or 
from well-informed nurses or caregivers (89%).
Utility before and after the first UTI (parameters U0 and U2) was estimated from EQ-5D and 
VAS measurements obtained at baseline and after 6 and 12 months (correcting for time). In 
addition, UTIs were assumed to have a short-term effect on utility for 2 weeks. Additional 
EQ-5D and VAS measurements were obtained in 123 participants with a clinically defined UTI 
(from 17 different LTCFs) every 3 days over 3 weeks after the UTI to estimate this effect. The 
utility decrement during the UTI was estimated as the difference between the average over 
figure 1. The state-transition model used in the economic evaluation. 
UTI = urinary tract infection.
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the first 2 weeks and the average over the third week (parameter ΔU, attributed to State 3 with 
parameter  U1 = U2 - ΔU x 14/30).
Costs
The economic model included two types of costs. The first was the costs of cranberry use 
(parameter c1). These costs were estimated at €439 annually (€0.62 per intake) based on one 
capsule twice a day, a market price of €44 for 180 capsules, on average 45 seconds of nursing 
time per capsule (estimated using time registrations), nursing time valued at €30 per hour,9 
and 97% adherence (1.00 euro = 1.37 U.S. dollar).
The second type of costs were the costs associated with each UTI (parameter c2, Table 1), 
including costs of UTI diagnostics and antibiotic treatment, additional care by the elderly-care 
physician, additional nursing care, and hospitalizations. Costs of UTI diagnostics and antibiot-
ic treatment per UTI were calculated from actual costs in patient records for each UTI (n = 548). 
Additional care by the elderly-care physician was estimated at on average €25 per UTI (10-30 
minutes of time, valued at €111 per hour9,10). Additional nursing costs during the 2 weeks after 
a UTI were estimated in proportion to the Care Dependency Scale,11 which measures 15 items 
of basic care needs, each rated on a 5-point scale (1 = completely dependent; 5 = completely 
independent). Hospitalizations costs were recorded for six UTIs (1% of n = 548), all in high-UTI-
risk participants. Costs per hospitalization ranged from €3,000 (for 6 days of normal hospital 
care) to €15,000 (for 7 days of normal care and 5 days of intensive care).9
Costs were presented in euros, at 2013 prices (updated if necessary using the general Dutch 
consumer price index).12 Included costs were all medical costs, which for this trial population 
coincided with the societal perspective.
Lifelong Outcomes The model shown in Figure 1 and Table 1 was used to extrapolate the 
trial period to lifelong outcomes. Life expectancy was calculated as the expected total time 
spent in States 1 to 4. QALYs were calculated by weighing the time in each state with the 
appropriate utility value, discounted at δ = 4%.13 Using this approach, the following formula 
for the difference in discounted QALYs between the cranberry and the placebo groups was 
derived:
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  
0
0 1 0 0
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         
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where T denotes the initial 2 months and S denotes the 1 month after the first UTI. A simi-
lar formula was derived for the discounted costs. The models for the cranberry and placebo 
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table 1. Parameters for the health-economic model, estimated from the trial data
Parameters estimated 
value
(95%Ci)
uti infection ratesb among low uti-risk participants
Rate before the first UTI, during the first two months (λ0) 0.32 (0.23 – 0.395)
Hazard ratio before first UTI, after first two months (λ1/λ0)
a,c 1.41 (0.77 – 1.857)
Hazard ratio after the first UTI (λ2/λ0)
c 4.02 (2.11 – 5.288)
uti infection ratesb among high uti-risk participants
Rate before the first UTI, during the first two months (λ0) 0.81 (0.68 – 0.94)
Hazard ratio before first UTI, after first two months (λ1/λ0)
a,c 0.75 (0.52 – 0.94)
Hazard ratio after the first UTI (λ2/λ0)
c 1.81 (1.35 – 2.18)
Mortality ratesb
Rate before the first UTI (μ0) 0.33 (0.29 – 0.38)
Hazard ratio during the first month after first UTI (μ1/μ0)
c 3.57 (2.00 – 4.81)
Hazard ratio after the first month after first UTI (μ2/μ0)
c 1.32 (0.87 – 1.67)
utilitiesd based on eQ-5d
Before the first UTI (U0) 0.37 (0.36 – 0.38)
Decrement after the first UTI (U2 – U0)
c 0.02 (-0.01 – 0.05)
Decrement during first two weeks after first UTI (ΔU)c 0.04 (0.01 – 0.07)
utilitiesd based on VAs 
Before the first UTI (U0) 0.73 (0.72 – 0.74)
Decrement after the first UTI (U2 – U0) 0.00 (-0.02 – 0.02)
Decrement during first two weeks after first UTI (ΔU) 0.03 (0.00 – 0.05)
Annual costs (€)
Annual costs of cranberry use (c1)
a 439 –
Costs per uti (€) 
Costs of diagnostics 8 (6 – 10)
Costs of antibiotic treatment 3 (2 – 4)
Costs of elderly care physician 25 (22 – 28)
Costs of additional nursing care 120 (49 – 194)
Costs of hospitalizations 40 (-8 – 74)
Total costs per (prevented or non-prevented) UTI (c2) 196 (111 – 278)
aOnly in the cranberry group
bAnnual event rate
cRelative or absolute change during the specified period, compared with the base value
dThe valuation of quality of life of the participants, on a scale anchored at 1 (perfect health) and 0 (as bad as dead)
UTI = urinary tract infection
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groups only differ in their value for the infection rate (λ1 and λ0, respectively) and in their value 
for the annual cranberry costs (c1 and 0, respectively).
statistical analysis
Uncertainty due to sampling error for the estimated lifelong outcomes was assessed using 
bootstrap analysis (using B = 10,000 bootstrap samples). For each bootstrap sample, all model 
parameters (Table 1) were re-estimated, and the lifelong formulae were used to estimate out-
come. The 95% confidence intervals (CIs) for the parameters and outcomes were assessed 
from the 2.5 and 97.5 percentiles among the bootstrap samples.10 Statistical analyses for the 
economic evaluation were performed in R version 2.13.0 (Vienna, Austria).
Depending on the willingness to pay (WTP) for obtained effectiveness, cranberry use is 
estimated to be cost-effective if it has a better net benefit (NB = WTP x effectiveness - costs) 
than placebo. Cost-effectiveness acceptability curves were used to plot the probability that 
cranberry use is more cost-effective than placebo as a function of WTP (estimated as the per-
centage of bootstrap samples in which cranberry use had a better estimated NB). Confidence 
intervals for the cost-effectiveness ratio were calculated as WTP values for which the differ-
ence in net benefit was not significantly different.14 The base-case CUA compared total soci-
etal costs with QALYs calculated from the Dutch tariff for the EQ-5D at a WTP of €40,000 per 
QALY.
results
effect of utis on mortality, utility, and costs
Quality of life was significantly but moderately worse during a UTI; comparing the first 2 
weeks after a UTI with the third week, averages were 0.341 versus 0.379 for the EQ-5D (differ-
ence 0.038, P = 0.02) and 0.727 versus 0.753 for the VAS (difference 0.026, P = 0.03). 
Mortality in the month after a first UTI was 3.6 times as great as in residents without a UTI 
(Table 1). After more than a month, the difference was not statistically significant.
The Care Dependency Scale was also significantly but moderately worse during a UTI (40.7 
vs 42.0; difference 1.2; P = 0.01), with an estimated 4% increase in nursing costs in the 2 weeks 
after a UTI. Total healthcare costs associated with (prevented) UTIs were estimated at €196, 
primarily consisting of the additional nursing care (61%), followed by hospitalization costs 
(20%), care by the elderly-care physician (13%), diagnostics (4%), and antibiotic treatment 
(2%).
high-uti-risk participants
Cranberry use on average prevented 0.09 clinically defined UTIs (0.69 vs 0.78, P = 0.32) dur-
ing the trial follow-up (of 289 vs 289 days, P = 0.99). The associated costs were estimated at 
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€3,800 per prevented UTI (95% CI = €1,300-infinity). Cranberry use did not prevent strictly 
defined UTIs during follow-up (0.28 vs 0.22, P = 0.30). From a lifetime societal perspective, the 
reduced clinical UTI infection rate resulted in improvements in other health outcomes and 
costs, although not significantly (Table 2). Life expectancy was estimated to be approximately 
2 weeks longer (0.044 years, 95% CI = -0.023-0.091). The savings on costs associated with UTIs 
were much smaller than the cranberry costs, use of cranberry capsules increased lifelong total 
costs by €941 (95% CI = €779-1,055). Whether this cost difference is economically accept-
able depends on how much one is willing to pay for the health improvement in terms of 
QALYs (Figure 2). For relatively low willingness to pay up to €20,000 per QALY, the probability 
that cranberry use is more cost-effective than placebo was estimated at less than 1% (in the 
base-case analysis using the EQ-5D). At €40,000 per QALY, the probability that cranberry use is 
cost-effective was estimated at 22%. When the VAS was used instead of the EQ-5D, more value 
was assigned to quality of life during the added life expectancy. As a result, the estimated 
probability that  cranberry use is more cost-effective than placebo at a willingness to pay of 
€20,000 and €40,000 per QALY was 16% and 53%, respectively (Figure 2).
The economic assessment would be more favorable to cranberry use if the costs of cran-
berry use were lower or the savings per prevented UTI were higher. The costs of cranberry 
figure 2. Cost-effectiveness acceptability 
curves, for high-urinary tract infection 
(UTI)-risk participants (the probability that 
cranberry use is more cost-effective than 
placebo, depending on how much one is 
willing to pay for a quality-adjusted life 
year (QALY), based on utility measured 
using EQ-5D or visual analog scale (VAS)).
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use would need to decrease from €439 to €300 to make cranberry and placebo equally cost-
effective. Similarly, the savings per prevented clinical UTI would need to increase from €196 to 
€1,704 to make cranberry and placebo equally cost-effective.
low-uti-risk participants
In the low-UTI-risk participants, because no effect of cranberry use on UTI infection rate was 
found, there was also no difference in the other health outcomes. The only difference was the 
estimated lifelong costs of €1,012 for cranberry use. As a result, it is highly unlikely that use of 
cranberry capsules is cost-effective in low-UTI-risk residents (probability < 3%, regardless of 
willingness to pay per QALY).
table 2.  Mean lifelong health-economic outcomes of treatment with or without cranberry, estimated from the health-
economic model.
outcome Cranberry Placebo difference (95%Ci)
low uti-risk
Number of UTIa,b 2.13 1.84 0.29 (-0.06 – 0.60)
Life expectancy a (years) 2.53 2.59 -0.06 (-0.14 – 0.05)
QALYs based on EQ-5Dc 0.83 0.85 -0.02 (-0.05 – 0.01)
QALYs based on VASc 1.69 1.73 -0.04 (-0.09 – 0.03)
Costs of cranberry use (€) 1012 0 1012 (863 – 1120)
Costs of diagnostics (€) 15 13 2 (-1 – 5)
Costs of antibiotic treatment (€) 5 4 1 (-1 – 2)
Costs of elderly-care physician (€) 47 40 7 (-2 – 15)
Costs of additional nursing care (€) 228 196 32 (-22 – 68)
Costs of hospitalizations (€) 76 65 11 (-13 – 23)
Total UTI costs (€) 1383 318 1065 (889 – 1183)
high uti-risk
Number of UTIa,b 2.75 2.96 0.21 (-0.42 – 0.04)
Life expectancy a (years) 2.45 2.40 0.05 (-0.02 – 0.09)
QALYs based on EQ-5Dc 0.81 0.79 0.02 (-0.01 – 0.03)
QALYs based on VASc 1.64 1.61 0.03 (-0.01 – 0.06)
Costs of cranberry use (€) 982 0 982 (814 – 1099)
Costs of diagnostics (€) 20 22 -2 (-4 – 1)
Costs of antibiotic treatment (€) 7 8 -1 (-2 – 1)
Costs of elderly-care physician (€) 61 66 -5 (-10 – 1)
Costs of additional nursing care (€) 298 323 -25 (-49 – 13)
Costs of hospitalizations (€) 99 107 -8 (-17 – 9)
Total UTI costs (€) 1467 526 941 (779 – 1055)
aUndiscounted
bLifelong, both first and other urinary tract infections (UTIs), using the clinical definition
cQuality adjusted life years (QALYs; life expectancy weighed by utility for quality of life
VAS = Visual Anolog Scale
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disCussion
This study investigated whether the use of cranberry capsules is more cost-effective than pla-
cebo based on data from a randomized controlled trial.5 In participants with low UTI risk, the 
use of cranberry capsules did not prevent UTIs, and consequently, their use is not cost-effec-
tive. In high-UTI-risk participants, there were fewer clinically defined UTIs. Moreover, there was 
a significant, but moderate, short-term effect of those UTIs on quality of life and care depen-
dency. Most of the QALY gain was due to the prevented UTI mortality, resulting in a gain in 
life expectancy of approximately 2 weeks. This relative 1.5% improvement in life expectancy 
is consistent with the estimated mortality attributable to UTI (7.7%) combined with the 26% 
treatment effect.5
Savings on prevented UTIs partly compensate for the costs of the cranberry capsules, but 
using a lifelong perspective, those savings added up to approximately €50. As a result, the 
overall cost difference is about equal to the costs of the cranberry capsules, estimated at €439 
per year or at €3,800 per prevented clinically defined UTI. The health gain in terms of QALYs 
was small in comparison with the costs, so use of cranberry capsules was not likely to be cost-
effective (22% for a WTP threshold of €40,000 per QALY).
options to improve cost-effectiveness
Cranberry use does not constitute a low-cost strategy to prevent UTIs.15 The estimated price 
for the capsules was lower than the price estimated previously (€0.24 vs CAN $0.73 ≈  €0.61),16 
but the overall costs per capsule were somewhat similar because of the added nursing time 
in the current study. The previous study estimated the costs per prevented UTI at CAN$1,890, 
which was acknowledged as quite high.16 That study suggested that cranberry use could be 
cost-effective if the strength or size of the cranberry product could be reduced without re-
ducing effectiveness. In the current study, a preventive effect was seen with the cranberry 
capsules after 2 months. It is unknown whether lowering the frequency after those 2 months 
would change not only the costs, but also the effect.
Second, the cost-effectiveness of cranberry use would also be more favorable in settings 
in which the savings per prevented UTI were higher. In the current study, these savings would 
need to be eight times as high to make cranberry and placebo equally cost-effective. This 
seems unrealistic for the Dutch LTCF setting, although in other healthcare systems, residents 
with UTIs may more frequently be referred to a hospital than the 1% in the current study 
population. Similarly, in noninstitutionalized vulnerable older persons, the savings associated 
with prevented UTIs may be higher because of the need for additional formal and informal 
care during and after a UTI.
Third, the high-UTI-risk criteria included diabetes mellitus, long-term catheterization, and 
UTI in the preceding year. Better identification of older persons at high UTI risk may also im-
prove cost-effectiveness.
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limitations
There are several complicating factors in analyzing cost-effectiveness in vulnerable older per-
sons in LTCFs. The first is how to value the residents’ health. According to the EQ-5D, health 
during the 2-week life expectancy gain was valued at approximately 40%, whereas according 
to the VAS, this gain would be valued at approximately 70%. In accordance with the study 
protocol, the EQ-5D was considered to be more appropriate than the VAS because the EQ-5D 
provides a societal valuation and because the descriptions it requires are less subjective than 
the valuations that the VAS requires.17 Consistent with the high percentage of participants 
with dementia (76%) and the high percentage of participants for whom family provided in-
formed consent (84%),5 nurses mostly provided the utility measures (89%), and little is known 
about the validity of proxy VAS valuations in a LTCF context. Considering the often poor health 
of LTCF residents, the VAS valuations appear high.
Another factor is the high costs of standard LTCF care, amounting to approximately €80,000 
annually in the Netherlands.9,18 Including these high costs in the analysis would make any life-
prolonging treatment too expensive, even if the treatment itself was cost free. In the analysis, 
the 2-week life expectancy gain would add approximately €1,500 to the costs associated with 
cranberry use, confirming the conclusion that use of cranberry capsules is not likely to be 
cost-effective. Dutch guidelines for economic evaluations in health care recommend includ-
ing costs associated with additional life time only if they are related to the primary interven-
tion, which was not the case in the current analysis.
Third, it was decided beforehand that the economic state/transition model would be based 
on the clinical definition, because it was expected that it would be more predictive of out-
come. Had the strict UTI definition been used for the model, the estimated effectiveness and 
cost-effectiveness would have been less favorable to the use of cranberry capsules, confirm-
ing the conclusion that use of cranberry capsules is not likely to be cost-effective.
Finally, this study was performed in Dutch LTCFs, where elderly-care physicians provide 
medical care.19-21 The results are not automatically generalizable to vulnerable older persons 
living at home. In LTCFs, medication prescription and distribution are well organized. Because 
the study capsules were added to the existing drug-dispensing system, participants rarely 
missed taking a capsule, reflected in a high adherence rate. For other settings, not only dif-
ferences in vulnerability and infection rates are expected, but also in adherence. Moreover, 
at home, cranberry capsules can be taken without the help of nurses, which would halve the 
costs of cranberry use.
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ConClusions
In high-UTI-risk residents, taking cranberry capsules may be effective in preventing UTIs but 
is not likely to be cost-effective in the investigated dosage, frequency, and setting. In low-UTI-
risk LTCF residents, taking cranberry capsules twice daily is neither effective nor cost-effective.
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The overall aim of this thesis was to explore the possibilities for and effects of prevention of 
clinical urinary tract infections (UTI) in vulnerable very old persons. 
The first part of this thesis investigates the effects of infections on functioning and exam-
ines which very old persons would benefit most from UTI prevention. Firstly, we focused on 
the most vulnerable very old persons, often with (advanced) dementia and with high and 
complex care dependency, in long-term care facilities (LTCF). For this, we studied changes 
in the natural course of care dependency in LTCF residents. The conclusions drawn from this 
prospective follow-up study are that the majority of surviving LTCF residents were stable in 
their care dependency status over two subsequent 6-month periods and that residents who 
are most highly dependent on care have an increased risk of mortality (Chapter 2). 
Secondly, within the Leiden 85-plus Study, we examined whether clinical UTI predict an 
increase in disability of the activities of daily living (ADL) among the oldest-old in the gen-
eral population (Chapter 3). The general population was studied to unravel how infections 
and disability co-occur. This study showed that in 86-year-old persons without ADL disabil-
ity, a clinical UTI is associated with a higher risk to develop ADL disability from age 86 years 
onwards. However, no such association was found for persons who already had disabilities 
related to ADL (Chapter 3). 
Thirdly, we investigated which factors are predictive of clinical UTI among the oldest-old 
in the general population. This study showed that cognitive impairment, ADL disability, self-
reported urine incontinence, and a one-year history of clinical UTI, are independent predic-
tive factors of an increased incidence of clinical UTI from age 86 onwards (Chapter 4). These 
predictive factors can be used to target preventive measures to the oldest-old at high risk of 
clinical UTI.
In summary, the first three studies presented in this thesis show that the majority of LTCF 
residents remained stable in their care dependency status, that clinical UTI are frequently 
present in vulnerable very old persons, and that these clinical UTI have consequences for daily 
functioning. Furthermore, there are factors that can be used to identify older persons at risk 
for developing clinical UTI. Thus, prevention of clinical UTI is important and it is possible to 
identify vulnerable very old persons at risk for developing clinical UTI. Therefore, we searched 
for preventive strategies which are suitable for the prevention of UTI in this specific popula-
tion.
Until now, there are no evidence-based interventions that show a decrease in clinical UTI in 
institutionalized populations;1 however, there is increasing evidence that cranberry products 
may lead to a decrease in the incidence of clinical UTI over a 12-month period, particularly 
in women with recurrent UTI.2-4 Although two studies reported that cranberry juice may be 
protective in older adults,5;6 the effectiveness of cranberry capsules in the protection against 
UTI in vulnerable older persons in LTCF had not yet been studied. Therefore, we designed the 
CRANBERRY study to assess the effectiveness and costs of cranberry capsule use to prevent 
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clinical UTI in LTCF residents, stratified for UTI risk at baseline. The results of the CRANBERRY 
study are described in the second part of this thesis. 
The CRANBERRY study (Chapter 5) shows that taking cranberry capsules twice daily results 
in a 26% lower incidence of clinically defined UTI compared to placebo in residents at high 
risk of UTI, but that cranberry use is unlikely to be cost-effective in the investigated dosage, 
frequency and setting (Chapter 6). In other words, although cranberry capsules reduce the 
number of clinical UTI in vulnerable very old persons living in LTCF, the capsules cost more 
than they save in relation to the costs of regular treatment of clinical UTI.
This chapter places the preventive care for vulnerable very old persons in a broader per-
spective and discusses the challenges and barriers of research in long-term care. The chapter 
ends by discussing the clinical impact of our findings for daily practice in long-term care and 
makes some recommendations for future research.
PreVentiVe CAre in VulnerABle VerY old Persons
Within preventive care for vulnerable older persons, the traditional prevention goals (such as 
preventing diseases and mortality) should be extended by goals such as preventing loss of 
quality of life and self-reliance7, and the prevention of discomfort. This will enable older per-
sons to be as independent and healthy as possible, in relation to their care needs and health 
problems. 
The most vulnerable older persons generally live in LTCF. These older persons with multi-
morbidity, functional decline and a high prevalence of cognitive impairment, are dependent 
on care. In this population, preventive care focuses particularly on loss of quality of life, mini-
mization of the impact of a disease, and reduction of the burden of this disease in the preven-
tion of complications, comorbidity and disability. In addition, preventive measures to achieve 
a dignified end-of-life are part of the preventive tasks (e.g. mouth care, and prevention of 
pressure ulcers, urinary retention and constipation) of professional caregivers in long-term 
care.
Depending on the goals,  a well-considered choice has to be made in the selection of a 
preventive measure in LTCF. When considering preventive strategies to prevent clinical UTI in 
long-term care, several topics need to be addressed: 
 1. Care dependency and the resident’s ADL status 
 2. Expected impact of clinical UTI prevention 
 3. Selection of residents at high risk for developing clinical UTI
 4. Challenge of diagnosing clinical UTI
 5. Selection of appropriate preventive treatment 
 6. Cost-effectiveness of clinical UTI prevention
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These six points will be discussed in detail below.
1. Care dependency and the resident’s Adl status 
In this thesis, changes in the natural course of care dependency were examined to shed light 
on how to manage and provide better tailored care (including prevention) for individual LTCF 
residents (Chapter 2). Awareness of the natural course of care dependency is essential for resi-
dents, as well as for their formal and informal caregivers, when considering therapeutic and 
end-of-life care options, as well as preventive measures. With this in mind, research among 
the oldest-old needs to include an assessment of the impact of a disease on an individual’s 
functional capacity and on maintaining their independence.8 
Since aging is often accompanied by a higher incidence of infections and an increase in 
ADL disability, it is important to establish whether there is a relation between infections and 
ADL disability. In addition, prevention of infections may also prevent a decline in ADL. But 
how do infections and disability in ADL co-occur? It is known that disability in ADL is indepen-
dently associated with the onset of nosocomial infections in hospitalized older persons,9 and 
is a risk factor for infections in LTCF.10,11 However, it is also known that, amongst the oldest-old 
in the general population, clinically diagnosed infections are predictive for the development 
of ADL disability in those without onset of ADL disability (Chapter 3). ADL disability can be 
considered as a risk factor for an infectious disease, but also as an outcome itself.8,9,11 
A decline in ADL in older persons has to be placed in a proper perspective. Other non-infec-
tious illnesses and chronic diseases, such as cardiopulmonary, neurological and musculoskel-
etal diseases, can also lead to ADL disability. In addition, under-nutrition and incontinence can 
contribute to a decline in ADL.12-14 A severe decline in ADL can even lead to a higher mortality 
rate,10 more care dependency, and a higher risk of being admitted to a LTCF.15 
2. expected impact of clinical uti prevention
In general, infections contribute to higher morbidity and mortality, infection outbreaks, in-
creased antimicrobial medication use, and additional costs in LTCF.16,17 In addition, the fre-
quent use of antibiotics contributes to more pathogens becoming multi-resistant to antibiotic 
treatment;18 moreover, prophylactic antibiotic use is controversial because of side-effects. 
Clinical UTI are common and account for 25% to 40% of all bacterial infections in LTCF.19-21 
They place a considerable burden on daily care and have serious consequences for vulnerable 
older persons living in LTCF. Clinical UTI not only cause several days of illness, but may have 
more severe consequences such as delirium, dehydration, urosepsis, hospitalization or even 
death22,23 and also lead to a deterioration in daily functioning, even when the infection is over 
(Chapter 3). Considering the impact of clinical UTI in LTCF residents, it seems important to 
prevent clinical UTI in these vulnerable older persons. 
In this thesis, several studies illustrate the high incidence of clinical UTI. Although the study 
in Chapter 3 shows a decline in ADL in the oldest-old who are not yet disabled, in the CRAN-
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BERRY study we were able to reduce the incidence of clinical UTI but were unable to show a 
reduction in functional decline or mortality. Because LTCF residents represent a vulnerable 
population, often with (advanced) dementia and high care dependency, the expected impact 
of clinical UTI in this population may be limited to mainly temporary discomfort, but can lead 
to higher care dependency, complications, and even mortality. 
3. selection of residents at high risk for developing clinical uti
Since preventive strategies are best applied to those persons at risk for developing UTI, it is 
important to know which factors predict clinical UTI in older persons. Within the oldest-old in 
the general population, a history of UTI, cognitive impairment, ADL disability and urine incon-
tinence, are independent predictive factors for developing UTI (Chapter 4). These predictive 
factors could be used to target preventive measures to the oldest-old at high risk of UTI. De-
spite that none of these predictive factors appear to be modifiable, they can be used to select 
individuals who will most benefit from preventive strategies. Selection of high-risk residents 
is a crucial first step in successful prevention of clinical UTI. 
Following the results of the 85-plus Study (Chapter 4), the CRANBERRY study showed that 
through selection of residents at low and high risk of UTI, it is possible to distinguish groups 
of LTCF residents with varying risks of clinical UTI. For example, in the CRANBERRY study, resi-
dents with long-term catheterization, diabetes mellitus, or at least one UTI in the preceding 
year, were considered to be at high risk. Although our high-risk residents were selected using 
these criteria, it is possible that the use of other criteria might have selected a group at even 
higher risk or with even more preventable UTI. Prediction rules to select residents at risk for 
UTI need further study in order to make a more efficient and effective prediction of the UTI 
risk in this specific population. Improved identification of older persons at high risk of UTI may 
also improve cost-effectiveness.
Another point to be taken into consideration is that a UTI risk assessment should be evalu-
ated regularly, because the risk for developing UTI can change over time. Moreover, a preven-
tive measure should not necessarily be applied ‘forever’. Additional research is required to 
develop rules related to ‘stopping’ because, for example, the preventive action of cranberry 
capsules can cease when a person has been one year free of UTI, and when no other risk fac-
tors are present. 
4. Challenge of diagnosing clinical uti
According to clinical guidelines (and also for many studies) the appropriate gold standard for 
diagnosing UTI is detection of the pathogen in the presence of inflammatory signs and clini-
cal symptoms of micturition.24,25 A less rigorous definition can easily lead to over-diagnosis 
and false conclusions.26 Although clinical UTI is a common bacterial infection in LTCF resi-
dents,1,27 diagnosing UTI in these vulnerable older persons remains a challenge. Factors such 
as impaired communication because of dementia, a high prevalence of incontinence, chronic 
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genitourinary symptoms, and a high frequency of positive urine cultures due to bacteriuria 
without complaints,28-30 make the diagnosis of UTI difficult. In addition, clinical symptoms of 
UTI are frequently absent31 and differentiating between asymptomatic and symptomatic UTI 
in this population is complicated.28,32 The use of the gold standard for diagnosing clinical UTI 
is not suitable for LTCF residents and would lead to substantial under-diagnosis. Thus, no un-
ambiguous criterion standard for diagnosing UTI is available for LTCF populations and most 
of the clinical criteria applied to ascertain UTI in these vulnerable residents are based on con-
sensus.33-36 
Generally, these consensus guidelines define a clinical UTI as the presence of specific and 
non-specific symptoms and signs of UTI, such as dysuria, change in the character of urine, and 
change in mental status, confirmed with a urinalysis to evaluate for evidence of the presence 
of nitrite and leukocyte esterase. A positive nitrite and leukocyte esterase test may indicate 
the presence of clinical UTI, and treatment with antibiotics may then start. Although UTI are 
often treated empirically,18 a urine culture may be necessary in LTCF residents with recurrent 
UTI to confirm the diagnosis and guide antibiotic treatment. In addition, the treatment of 
clinical UTI in LTCF residents is similar to that of older patients in the community, but with 
more emphasis on individualized and tailored antimicrobial therapy.24,36
Because the confirmation of clinical UTI in LTCF residents remains difficult, in the CRAN-
BERRY study two definitions for UTI were used, i.e. a clinical one and a ‘strict’ UTI definition 
(Chapter 5). The strict UTI definition is based on a scientific approach and includes the pres-
ence of micturition-related signs and symptoms, confirmed with a positive culture or dipslide. 
Using only this strict UTI definition probably leads to under-estimation of the true incidence 
of UTI in LTCF residents and could be less sensitive for our LTCF population. 
To make research possible in a ‘real world’ LTCF population, besides the strict definition, 
a clinical UTI definition was used. This clinical definition is a broad and practical definition, 
follows the clinical practice guidelines for LTCF residents,25,37 and is based on the experience 
of elderly care physicians and nursing staff. Experienced staff can achieve an even higher 
diagnostic precision than that acquired with a urine culture.38 There is also evidence that 
micturition-related signs and symptoms are predictive for UTI.28 Although use of the clinical 
definition can lead to an over-estimation of UTI, it closely reflects clinical care in LTCF and adds 
knowledge to the practice guidelines to assist physicians in their decision-making. Because 
the beneficial effect of cranberry capsule use was only found when using our clinical UTI defi-
nition, the presence of false-positive clinical UTI is limited. Furthermore, the cost-effectiveness 
analysis described in this thesis (Chapter 6), also illustrates the relevance of the clinical defini-
tion, as clinical UTIs were followed by a significant deterioration in quality-of-life and survival, 
and an increase in care dependency and costs. 
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5. selection of appropriate preventive treatment
As very old people can differ considerably from one another with respect to their health, and 
functional and cognitive status, instead of a ‘one size fits all’ approach a personalized pre-
ventive care approach is needed. In addition, it is recommended to incorporate ‘lag time to 
benefit’ in the preventive care decisions for older populations.39 Lag time to benefit is defined 
as the period between an intervention and the moment that improved health outcome is 
observed.40 Incorporating lag time estimates into preventive care for vulnerable older persons 
will encourage a more explicit consideration of the risks and benefits of prevention.41  
In this thesis, cranberry use for the prevention of clinical UTI showed a positive treatment 
effect from 2 months of follow-up onward, with a risk reduction of 22% in high UTI-risk resi-
dents during the 12-month follow-up (Chapter 5). This level of risk reduction seems to be 
meaningful in this specific population in which clinical UTI are frequently present.
The CRANBERRY study showed positive effects of cranberry capsule use for UTI in LTCF resi-
dents; other benefits of cranberry capsules may also be considered. For example, in daily prac-
tice, cranberry use may also reduce antibiotic prescription, including inappropriate prescrip-
tions. In other words prevention with cranberry may lead to even less antibiotic resistance in 
long-term care. Also, less clincial UTI will lead to a reduction in the burden of UTI symptoms 
and to less discomfort.
It is important to realize that many preventive measures have not yet been tested in LTCF 
populations. More research is needed in this specific population to achieve an optimal, per-
sonalized and tailored prevention strategy, in which prevention is focused on increased qual-
ity of life, minimization of the impact of disease,  reduction of the burden of disease in the 
prevention of complications, comorbidity and disability, and a dignified end-of-life. 
Thus, prevention in LTCF needs to be examined in contexts other than the traditional pre-
vention approach which has the prevention of disease and mortality as its ultimate goal. A 
new framework for preventive care in LTCF needs to be developed which involves both the 
older person and their informal caregiver(s). Within the individualized preventive care for 
vulnerable very old persons, the practical feasibility of interventions needs to be taken into 
account, as well as an effective implementation in daily care which includes education, knowl-
edge and professional development, regulations, and financial considerations.
6. Cost-effectiveness of clinical uti prevention 
Justifying the implementation of new prevention strategies not only requires evaluation of 
its effectiveness, but also requires economic evaluation. For an economic evaluation in long-
term care the impact of clinical UTI on the resident’s health is relevant, and the resident’s 
quality of life plays an important role in the societal valuation. The ultimate goal in long-term 
care is not simply adding ‘years to life’ but adding ‘quality of life to years’. Therefore, the costs 
and benefits of interventions to prevent clinical UTI in LTCF populations need to be carefully 
weighed.
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The CRANBERRY study shows that it is unlikely that cranberry capsule use will be cost-
effective in the investigated dosage, frequency and setting (Chapter 6). However, cranberry 
capsules can be ‘efficient’ from the perspective of the individual resident with a high risk of 
UTI, resulting in a lower incidence of clinical UTI, less impact of UTI on the resident’s health 
(e.g. less disability in ADL, care dependency and less discomfort), and a better quality of life. 
Also, less antibiotic use and (probably) less antibiotic resistance is likely to lower the costs. The 
costs attributed to antibiotic resistance were not discounted in the CRANBERRY study.
Economic evaluations usually express the effects of the intervention in the number of life-
years gained and in health-related quality of life.42 Preferably, a cost-utility analysis is per-
formed for economic evaluations, whereby the effectiveness of the intervention in terms of 
quality-adjusted life years (QALYs) is expressed in a cost-utility ratio per QALY. This ratio is 
defined as the amount of money the society is willing to pay to gain one QALY.43;44 The CRAN-
BERRY study shows that the health gain in terms of QALYs was small in comparison with the 
costs. Most of this gain was due to the prevented clinical UTI mortality, i.e. a QALY gain in life 
expectancy of two weeks (Chapter 6). Although two weeks seems relatively small, in a vulner-
able LTCF population with a life expectancy of around 1.5 years after admission to a LTCF, 
this is relatively large. The six-month mortality rate in LTCF residents with advanced dementia 
ranges from 18% to 37%,45,46 and the overall 2-year mortality rate after institutionalization is 
57%.47 
Usually the QALYs are based on health-related quality of life, measured using the Euro-
pean Quality of Life utility measure (EQ-5D); this is a generic preference-based measure using 
a health state classification system with five dimensions (mobility, self-care, usual activities, 
pain/discomfort, and anxiety/depression).48 Although use of the EQ-5D allows to compare 
economic evaluations internationally, it is less suitable for use in the LTCF setting.49-51 Nor-
mally, quality of life measurements require the resident’s self-assesment of their fulfilment 
and impairment in daily life;50 however,  because the most vulnerable people, often with (ad-
vanced) dementia, live in LTCF, the proxy (e.g. the responsible nurse, or relative) generally pro-
vides the utility measure. However, there is evidence that the rating of quality of life by proxy 
is influenced by the personal and/or professional characteristics of the proxy, the nature of the 
relationship, the time spent with the resident, the stage of dementia, and also the caregiver 
burden.49,50 Thus, there is often a discrepancy between the quality of life rating acquired from 
the residents themselves and that of their proxy, although the viewpoint of the proxy appears 
to be important when rating the EQ-5D.52 Despite that, the responsible nurse is well acquaint-
ed with the residents, it is difficult to rate the resident’s pain/discomfort and anxiety/depres-
sion, especially in residents suffering from dementia. The EQ-5D is too narrowly focused and 
does not cover the domains relevant to the quality of life of persons with dementia. In the 
CRANBERRY study the EQ-5D had to be filled in by a professional proxy because 76% of the 
participants had dementia. A recently developed prototype of the Dementia Quality of life In-
strument (DQI) seems more suitable, but has not yet been tested in a large LTCF population.49 
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Another aspect related to economic evaluations in LTCF needs to be adressed, i.e. how do 
we measure the additional nursing care for LTCF residents who already have continous care? 
Until now, there is no standard for measuring the costs of additional nursing care in LTCF resi-
dents who are already highly care dependent. Therefore, we calculated the additional nursing 
costs during the two weeks following a clinical UTI, by estimating the proportion of change 
on the Care Dependency Scale (Chapter 6).53 Although this method was suitable for our study, 
additional research is required to validate this method. 
In the light of all these difficulties related to economic evaluations in long-term care, there 
is an urgent need for a more suitable instrument to conduct economic evaluations, because 
the present methods may never demonstrate cost-effectiveness. 
reseArCh in long-terM CAre fACilities: ChAllenges And BArriers
The above mentioned substantive and methodological points show that research in LTCF 
populations is challenging and needs specific knowledge and a specific infrastructure. This 
section discusses the challenges and barriers to research in LTCF populations. 
The proportion of older people is steadily rising worldwide; moreover, they live longer and 
manage their daily activities for longer than ever before.54 However, these people also have a 
higher risk of higher care dependency, institutionalization and mortality.55,56 Admission to a 
LTCF is usually the result of a complex interaction of problems in many domains, in which care 
and treatment are insufficient to handle all the needs that the individual resident has. Espe-
cially behavioral problems (e.g. wandering, aggression, delusions), as well as depression and 
anxiety, apathy, resistance to care, functional impairment, incontinence, and informal caregiv-
er burden, are reasons for institutionalization.57,58 Therefore, in the future, LTCF will probably 
admit only the most problematic and vulnerable persons, often with (advanced) dementia. 
Prevention of loss of quality of life and self-reliance is challenging in this vulnerable popula-
tion. However, an even greater challenge is to minimize the impact of a disease, and reduce 
the burden of this disease in the prevention of complications, comorbidity and disability; all 
this requires specific insight and solid evidence. Therefore, research is needed in LTCF popula-
tions to generate specific knowledge that also takes into account implementation of this new 
knowledge into daily practice. 
LTCF residents are often excluded from participation in research, sometimes due to the 
high prevalence of cognitive impairments (e.g. dementia) and sometimes due to medico-
ethical considerations.59 Also, difficulty in acquiring informed consent for study participation 
from representatives is often a reason for not conducting research in this population. In addi-
tion, various methodological issues may form a barrier to research in an LTCF population: for 
example, difficulties in formulating clear research outcomes or clinical endpoints, problems 
in defining a clear and unambiguous diagnosis of the disease, the high mortality rate in this 
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population, and the related high level of drop-out during a study. Moreover, some logistic 
challenges in performing research in LTCF are present, such as obtaining permission from the 
directors for their organization(s) to participate in the research project and the geographical 
distance between the participating organizations; often, this distance makes data collection 
and monitoring of the research project both difficult and costly. 
Most research in LTCF is pragmatic and will take place in a ‘real world’ LTCF population. 
Therefore, research in LTCF requires a specific infrastructure as well as a considerable effort to 
enable research in this population. In 2003 the formation of academic nursing home research 
networks was started in the Netherlands. Currently, in 2014, there are five networks (located 
in Amsterdam, Groningen, Leiden, Maastricht, and Nijmegen) that have expertise related to 
performing research in complex care among vulnerable persons living in LTCF. The mission of 
an academic nursing home research network includes the development of an infrastructure 
for research.60,61 Care professionals collaborate with scientists of a university medical center 
to develop, implement, and test initiatives to improve quality of care.60 Within this structure, 
university and practice are closely linked. Research outcomes will be directly implemented in 
daily practice and in the education/training of care professionals; hopefully, all this will serve 
to improve directly patient care.
CliniCAl iMPACt And reCoMMendAtions for future reseArCh 
Based on the work presented in this thesis, the following conclusions can be drawn:
1. The natural course of care dependency is a dynamic process. LTCF residents can either 
improve or deteriorate in their care dependency status during their stay in a LTCF. Regular 
and simple assessment of the care dependency status is important, since this allows nursing 
staff to become more aware of the variability in the care dependency status of their residents, 
manage care, anticipate residents’ care needs, and provide better tailored care for individual 
residents. Awareness of the course of care dependency is essential for residents, as well as for 
their formal and informal caregivers, when considering therapeutic, palliative, and end-of-life 
care options. Although care dependency can be influenced by individually-tailored interven-
tions, these types of interventions need additional research.
2. In older persons without ADL disability at 86 year of age, clinical infections predict the 
development of disability in ADL from age 86 years onwards. These infections may be used as 
a predictor for ADL disability in the oldest-old who are not yet disabled. General practitioners 
and elderly care physicians should be vigilant when older persons without ADL disability have 
an infection. Besides treatment, they may start active functional rehabilitation to maintain 
independence in ADL. Future studies need to address whether the prevention of infections, 
a quick recovery after infections, and functional rehabilitation, are beneficial in the oldest-
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old in the general population to maintain independence in ADL and to avoid adverse health 
outcomes.
3. Diagnosing clinical UTI is challenging in vulnerable very old persons. Although several 
guidelines are available to assist physicians in the diagnosis of clinical UTI in this population, 
there is no unambigous definition of clinical UTI. The current guidelines are not optimal for 
clinical decision-making, or for a 100% confirmation of clinical UTI. Additional studies are re-
quired to further refine these consensus guidelines and to establish how to optimally diag-
nose clinical UTI in vulnerable very old persons.
4. It is possible to select vulnerable very old persons at high risk for developing UTI. LTCF 
residents with long-term catheterization, diabetes mellitus, or at least one UTI in the preced-
ing year, are considered to be at high risk of UTI. It is possible that the use of other criteria 
would have selected a group with even higher risks or even more preventable UTI. Therefore, 
prediction rules to select residents at risk for UTI need to be studied to enable a more efficient 
prediction of the UTI risk in this specific population. In addition, it is recommended to evalu-
ate UTI risk on a regular basis, because the risk for developing UTI can change over time.  
5. The use of cranberry capsules (twice daily) is effective in the prevention of clinical UTI 
in LTCF residents at high risk of UTI. The capsules reduce the incidence of clinical UTI and 
thereby reduce the days of illness and the negative consequences of UTI, e.g. a reduction of 
the burden of the symptoms of UTI and less discomfort. The use of the capsules was shown 
not to be cost-effective; nevertheless, for reasons of effectiveness, it is still recommended to 
give residents at high risk of UTI preventive treatment with cranberry capsules.
Finally, additional studies are required to investigate whether, for example, clinical UTI pre-
vention with cranberry capsules is effective in providing improvement in care from the per-
spective of the resident. In this case, the care improvement should focus mainly on quality of 
life, minimization of the impact of a disease, and a reduction in the burden of this disease in 
the prevention of complications, comorbidity and disability. To stratify residents and to make 
a well-considered choice for the indicated preventive interventions, assessment of the impact 
of the disease on an individual’s functional capacity and their ability to maintain indepen-
dence, is recommended. 
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Urinary tract infections (UTI) are among the most frequently reported infections among older 
persons. Annually, 20% of all older persons visit their general practitioner for a UTI and about 
50% of the residents in long-term care facilities (LTCF) get a UTI. This type of infection not only 
causes several days of illness but may have more severe consequences for older persons, such 
as a decline in functioning, as well as delirium, dehydration, urosepsis, hospitalization, or even 
death. It is generally assumed that infections also lead to a general decline in functioning, 
which is often irreversible and can cause a cascade of general deterioration, more care depen-
dency, and a higher mortality risk. In addition, it is known that disability in activities of daily 
living (ADL) is independently associated with the development of infections. Considering this 
negative impact of UTI, we were particularly interested in how to prevent UTI in vulnerable 
very old persons.
To avoid the possible negative effects of UTI in vulnerable older persons, interventions 
are needed. To more efficiently prevent UTI and their subsequent negative consequences it 
is important to identify older persons at risk for UTI. Among vulnerable older persons, an in-
creasing age, diabetes mellitus, stroke, urine incontinence, prior history of UTI, and impaired 
functional and cognitive status are predictive for the development of UTI. A first step towards 
effective prevention of UTI in older persons is to gain insight into whether these factors also 
play a role in the occurrence of UTI in the oldest old. If these factors are known, it should be 
easier to detect the group of oldest old with an increased risk of UTI. 
The use of prophylactic antibiotics in older persons at risk remains controversial because 
of the associated side-effects as well as antibiotic resistance. In addition, no other evidence-
based interventions are known to decrease UTI in institutionalized populations. However, 
prophylaxis with cranberry is a potential prevention strategy. Cranberries contain proan-
thocyanidins, which are stable compounds with anti-adhesion activity against, for example, 
Escherichia coli. Although two studies have reported that cranberry juice may be protective 
in older adults, the effectiveness of cranberry capsules in the protection against UTI in vulner-
able very old persons in LTCF has not yet been studied.
The general aim of this thesis is to study the possibilities for and the effects of the preven-
tion of UTI in vulnerable very old persons.
PArt one: CorrelAtes of urinArY trACt infeCtions
Chapter 2 focuses on the care dependency of the most vulnerable very old persons in LTCF, 
often with (advanced) dementia and with high and complex care dependency. In a prospec-
tive follow-up study in 21 Dutch LTCFs, changes in care dependency were examined over two 
6-month periods, and the possible predictive factors of change and the effect of care depen-
dency on mortality were explored. The changes in care dependency were examined to shed 
light on how to manage care and provide better tailored care for individual LTCF residents. A 
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total of 890 LTCF residents with a median age of 84 years participated. At baseline, and at 6 
and 12 months, the care dependency status was assessed by the nursing staff using the Care 
Dependency Scale (CDS). The CDS comprises 15 items measuring basic care needs of LTCF 
residents. 
The conclusions drawn from this study are that the majority of surviving LTCF residents 
were stable in their care dependency status over two subsequent 6-month periods, and that 
residents who are most highly dependent on care have an increased mortality risk. A 1-point 
decrease in CDS score between 0 and 6 months was related to an increased mortality risk of 
4%. In addition, gender, age, urine incontinence, dementia, cancer and baseline care depen-
dency status predict an increase in care dependency over time. The results of this study indi-
cate that residents, and their formal and informal caregivers, need to be aware of the natural 
course of care dependency when considering therapeutic and end-of-life care options, as well 
as preventive measures, in long-term care. 
Because infections are more common in vulnerable older persons and these infections may 
also have negative consequences for their (ADL), the study in Chapter 3 examined whether 
UTI or lower respiratory tract infections predict an increase in disability of ADL among the 
oldest old in the general population. This study used data from the Leiden 85-plus Study (a 
population-based prospective follow-up study) and was performed to establish whether in-
fections at old age predict an increase in ADL disability, stratified for the presence of ADL 
disability. A total of 473 persons aged 86 years participated. ADL disability was determined 
at baseline and annually thereafter during 4 years of follow-up, using the 9 ADL items of the 
Groningen Activity Restriction Scale.
The study showed that in persons without disability in ADL between age 85 and 86 years, 
infections are associated with a 1.6 times higher risk to develop ADL disability from age 86 
years onwards compared with older persons without infections. However, no such association 
was found for persons who already had disabilities related to ADL. In addition to treatment, 
active functional rehabilitation may be important to restore independence in ADL.
In order to take effective preventive measures against UTI, especially older persons who 
are at increased risk to develop UTI should be selected. Therefore, the study in Chapter 4 
determined which predictive factors of UTI among the oldest old in the general population 
were predictive for UTI. This population-based prospective follow-up study (also based on 
data from the Leiden 85-plus Study) showed that cognitive impairment, ADL disability, self-
reported urine incontinence and a one-year history of UTI, are independent predictive factors 
of an increased incidence of UTI from age 86 onwards. These predictive factors can be used 
for the development of a clinical prediction rule to select the most appropriate persons for 
preventive strategies.
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PArt two: the CrAnBerrY studY
Until now, apart from general hygienic precautions, adequate hydration, regularly toilet visits 
and sufficient urination (bladder emptying), there are no evidence-based non-antibiotic inter-
ventions that show a decrease in clinical UTI in institutionalized populations. However, there 
is increasing evidence that cranberry products may lead to a decrease in the incidence of 
clinical UTI over a 12-month period. Although two studies have reported that cranberry juice 
may be protective in older adults, the effectiveness of cranberry capsules to protect against 
UTI in vulnerable older persons in LTCF had not yet been studied; therefore, we designed the 
CRANBERRY study. 
The CRANBERRY study is a double-blind randomized placebo-controlled multi-center trial, 
in which a total of 21 LTCF from the University Network for the Care sector in South-Holland 
(UNC-ZH) participated. The CRANBERRY study assesses the effectiveness and costs of cran-
berry capsule use to prevent clinical UTI in vulnerable older persons living in LTCF, stratified for 
UTI risk at baseline. Participants were stratified according to UTI risk at the start of the study. 
Participants with long-term catheterization, diabetes mellitus, and at least one UTI in the pre-
ceding year, were considered to be at high risk for UTI. In total, 928 residents (225 men and 
703 women) aged over 65 years of age were randomized in two groups: one group received 
cranberry capsules and the other group a placebo. Cranberry and placebo capsules were pro-
vided twice daily for 12 months. 
The primary outcome was the incidence of UTI. However, because diagnosing UTI in vul-
nerable older persons is difficult, the CRANBERRY study not only used the prevailing scientific 
gold standard (strict definition), but also used the clinical diagnosis made for each individual 
resident (clinical definition). The strict definition is based on a scientific approach, which al-
ways involves the presence of clinical symptoms and the presence of bacteria in the urine. In 
contrast, the clinical definition varies between residents and is therefore a broad and practical 
definition, following current clinical practice guidelines and based on clinical agreement of 
‘elderly care’ physicians and the nursing staff.
The study in Chapter 5 investigates the effectiveness of cranberry capsule use in the pre-
vention of UTI in vulnerable older persons living in LTCF. The CRANBERRY study shows that the 
use of cranberry capsules reduced the number of clinical UTI by 26% in LTCF residents with a 
high UTI risk; this treatment effect occurs after 2 months of capsule use. Also, more than 20% 
of the residents no longer developed any UTI at all. No difference in incidence was found in 
residents with low UTI risk. For UTI defined according to the strict definition, no difference was 
found in UTI incidence between residents who used cranberry or placebo capsules.
The use of cranberry capsules requires not only evaluation of its clinical effectiveness but 
also an examination of its cost-effectiveness. Therefore, the economic evaluation presented 
in Chapter 6 investigated the effect of clinical UTI on health and costs and examined whether 
the preventive use of cranberry capsules in LTCFs is cost-effective. This study concluded that, 
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in high UTI risk residents, taking cranberry capsules is unlikely to be cost-effective in the inves-
tigated dosage, frequency and setting. In other words, although cranberry capsules reduce 
the number of clinical UTI in vulnerable very old persons living in LTCF, the capsules cost more 
than they save in relation to the costs of regular treatment of clinical UTI.
Finally, Chapter 7 presents a general discussion on the main findings of the work presented 
in this thesis. The chapter also reflects on the difficulties in diagnosing UTI in vulnerable older 
persons with dementia, considers the clinical implications of our findings for daily practice in 
long-term care, and makes some recommendations for future research. The preventive care 
for vulnerable very old persons is placed in a broader perspective and the challenges and bar-
riers of research in long-term care are discussed. 
The first three studies presented in this thesis show that clinical UTI are frequently pres-
ent in vulnerable very old persons and that these clinical UTI can have consequences for the 
daily functioning of the oldest old who are not yet disabled. In addition, the majority of LTCF 
residents remained relatively stable in their care dependency status. Furthermore, it was es-
tablished that some factors can be used to identify older persons at risk for developing clinical 
UTI. Thus, prevention of clinical UTI is important and it is possible to identify vulnerable very 
old persons at risk for developing clinical UTI.
The results of the CRANBERRY study allow to conclude that the use of cranberry capsules 
(twice daily) is effective in the prevention of clinical UTI in LTCF residents at high risk of UTI. 
The capsules reduce the incidence of clinical UTI and thereby reduce the days of illness and 
the negative consequences of UTI, e.g. reducing the burden of the symptoms of UTI and less 
discomfort. Although the use of the capsules was not cost-effective, for reasons of effective-
ness it is still recommended to give residents at high risk of UTI preventive treatment with 
cranberry capsules.
Because the confirmation of clinical UTI in LTCF residents remains difficult, in the CRAN-
BERRY study two definitions for UTI were used, i.e. a clinical one and a strict UTI definition. The 
appropriate scientific ‘gold standard’ for diagnosing UTI is detection of the pathogen in the 
presence of inflammatory signs and clinical symptoms of micturition. However, factors such 
as impaired communication due to dementia, high prevalence of incontinence, chronic geni-
tourinary symptoms and a high frequency of positive urine cultures due to bacteriuria, with-
out being clear whether these bacteria are from the urine bladder or from the environment 
after urination, makes the diagnosis of UTI even more difficult. The use of the ‘gold standard’ 
for diagnosing clinical UTI is not suitable for LTCF residents and will probably lead to substan-
tial underdiagnosis. As a result, no unambiguous criterion standard is available for diagnosing 
UTI in LTCF populations; most clinical criteria to ascertain UTI in these vulnerable residents are 
based on consensus about grouped clinical manifestations, as presented in clinical guidelines. 
Currently, these guidelines define a clinical UTI as the presence of specific and non-specific 
symptoms and signs of UTI, such as dysuria, change in the character of urine, and change in 
mental status, confirmed with a urinalysis to evaluate the evidence of the presence of nitrite 
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and leukocyte esterase. UTI are often treated empirically, but a urine culture may be necessary 
in LTCF residents with recurrent UTI to confirm the diagnosis and guide antibiotic treatment.
Although several guidelines are available to assist physicians in the diagnosis of clinical UTI 
in this population, no unambiguous definition of clinical UTI is available. The current guide-
lines are not optimal for clinical decision-making or for a 100% confirmation of clinical UTI. 
Additional studies are required to further refine these consensus guidelines and to establish 
how to optimally diagnose clinical UTI in vulnerable very old persons.
Within the preventive care for vulnerable older persons, the traditional prevention goals 
(such as preventing diseases and mortality) could be extended by goals such as preventing 
loss of quality-of-life and self-reliance, and the prevention of discomfort. Because the most 
vulnerable older persons generally live in LTCF a well-considered choice has to be made in 
the selection of a preventive measure in this population. Additional studies are required to 
investigate whether prevention is effective in providing improvement in care from the per-
spective of the resident. Care improvement in LTCF needs to focus mainly on quality-of-life, 
minimization of the impact of a disease, and a reduction in the burden of this disease in the 
prevention of complications, comorbidity and disability. All this requires specific insight and 
solid evidence. Therefore, research in LTCF populations needs specific knowledge that also 
takes into account the implementation of this new knowledge into daily practice and a spe-
cific infrastructure.
Future research in LTCF can best be performed within an academic nursing home research 
network, such as the UNC-ZH. An academic nursing home network has expertise related to 
performing studies in complex care among vulnerable older persons living in LTCF. Within 
this network, care professionals collaborate with scientists of a university medical center to 
develop, implement, and test initiatives to improve quality of care. Within this structure, uni-
versity and practice are closely linked and research outcomes can be directly implemented in 
the daily practice and education of care professionals.

ChAPter 9
Samenvatting

Samenvatting
131
Urineweginfecties zijn veel voorkomende infecties bij ouderen. Jaarlijks meldt 20% van de ou-
deren zich bij de huisarts met een urineweginfectie en krijgt ongeveer 50% van de ouderen in 
het verpleeghuis een urineweginfectie. Urineweginfecties veroorzaken niet alleen specifieke 
klachten en enkele dagen van algemeen ziek zijn, maar kunnen ook meer ernstige gevolgen 
hebben voor de oudste ouderen, zoals het optreden van verwardheid (delirium), uitdroging 
(dehydratie), urosepsis (bloedvergiftiging door een urineweginfectie) en zelfs leiden tot een 
ziekenhuisopname of overlijden. Over het algemeen wordt aangenomen dat infecties een 
algemene achteruitgang in het dagelijks functioneren kunnen veroorzaken. Deze achteruit-
gang kan mogelijk leiden tot meer zorgafhankelijkheid en een hoger risico op overlijden. 
Daarnaast is bekend dat een beperking in het dagelijks functioneren in verband kan worden 
gebracht met het ontstaan van nieuwe infecties. De kans op deze complicaties is groter bij 
kwetsbare ouderen. Het is dus belangrijk om urineweginfecties bij vooral kwetsbare oudste 
ouderen te voorkomen.
Om de mogelijke negatieve gevolgen van urineweginfecties bij kwetsbare oudste ouderen 
met een verhoogd risico te voorkomen, zijn preventieve interventies nodig. Uit de literatuur 
blijkt dat een toenemende leeftijd, diabetes mellitus, hersenbloeding, urine incontinentie, 
een eerder doorgemaakte urineweginfectie en een verminderd dagelijks en cognitief functi-
oneren voorspellende factoren van een urineweginfectie zijn. Een eerste stap naar een doel-
matige preventie van urineweginfecties bij ouderen, is het inzicht krijgen of deze factoren ook 
een rol spelen bij het ontstaan van een urineweginfectie bij oudste ouderen. Als deze factoren 
bekend zijn kunnen ouderen met een verhoogd risico op urineweginfecties makkelijker op-
gespoord worden.
Het preventief gebruik van antibiotica bij ouderen is werkzaam, maar omstreden door 
onder andere bijwerkingen en de afgenomen gevoeligheid van bacteriën voor antibiotica. 
Daarnaast zijn er tot op heden geen andere wetenschappelijk onderbouwde interventies be-
kend die urineweginfecties bij verpleeghuisbewoners kunnen voorkomen. Een goed alter-
natief kan het gebruik van cranberry’s (veenbessen) zijn. Cranberry’s bevatten proanthocya-
nidine, dat er onder meer voor zorgt dat bacteriën, waaronder Escherichia coli, zich niet aan 
de blaaswand kunnen hechten en daardoor geen infectie meer kunnen veroorzaken. Er zijn 
tot nu toe twee onderzoeken bekend die aantonen dat cranberrysap mogelijk beschermend 
kan werken bij ouderen, maar de effectiviteit van het gebruik van cranberry capsules om uri-
neweginfecties bij kwetsbare oudste ouderen in verpleeghuizen te voorkomen, is nog niet 
eerder onderzocht.
Het doel van dit proefschrift is om de mogelijkheden voor, en de gevolgen van preventie 
van urineweginfecties te onderzoeken bij verpleeghuisbewoners.
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deel 1: fACtoren die sAMenhAngen Met urineweginfeCties
In hoofdstuk 2 wordt de zorgafhankelijkheid van verpleeghuisbewoners belicht, de meest 
kwetsbare groep oudste ouderen. In een prospectieve follow-up studie in 21 Nederlandse 
verpleeghuizen is de verandering in zorgafhankelijkheid bestudeerd gedurende twee aan-
sluitende perioden van ieder 6 maanden. De mogelijke voorspellende factoren van zorgaf-
hankelijkheid en het effect op sterfte zijn in kaart gebracht. In totaal hebben 890 verpleeg-
huisbewoners met een mediane leeftijd van 84 jaar, aan de studie meegedaan. Bij de start van 
de studie en na 6 en 12 maanden is de mate van zorgafhankelijkheid door de verzorgende 
gemeten met de Care Dependency Scale (CDS). De CDS bestaat uit 15 items, die betrekking 
hebben op de basiszorgbehoeften van verpleeghuisbewoners. 
Tijdens de studie bleek de zorgafhankelijkheid van de meerderheid van de verpleeghuis-
bewoners over een periode van 6 maanden stabiel. Echter, de meest zorgafhankelijke ver-
pleeghuisbewoners hadden een toegenomen risico op overlijden. Eén punt minder op de 
CDS in de eerste 6 maanden bleek gerelateerd aan een toegenomen risico op overlijden van 
4% in de daarop volgende 6 maanden. Daarnaast waren geslacht, leeftijd, urine incontinentie, 
dementie, kanker en de zorgafhankelijkheid bij de start van de studie onafhankelijke voor-
spellers voor een toename van zorgafhankelijkheid over de tijd. Deze resultaten kunnen ver-
pleeghuisbewoners, hun mantelzorgers en professionele zorgverleners meer bewust maken 
van het verloop van zorgafhankelijkheid en het kiezen van op de individuele bewoner afge-
stemde, behandeling, preventie en palliatieve zorg.
Omdat infecties vaker voor komen bij kwetsbare ouderen en daardoor mogelijk ook ne-
gatieve gevolgen kunnen hebben voor het dagelijks functioneren van deze ouderen, is in 
hoofdstuk 3 onderzocht of infecties van de urinewegen en lage luchtwegen op oudere leef-
tijd een toename van beperkingen in activiteiten van het dagelijks leven (ADL) voorspellen. 
Deze studie was onderdeel van de Leiden 85-plus Studie, een observationele prospectieve 
cohort studie in de algemene bevolking. Van de 473 deelnemers van 86 jaar werden aan het 
begin van de studie en daarna jaarlijks gedurende 4 jaar follow-up, met behulp van de 9 ADL 
items van de Groningen Activity Restriction Scale beperkingen in ADL vastgesteld.
De studie toonde aan dat oudste ouderen die een infectie tussen het 85e en 86e jaar had-
den, een 1,6 keer hoger risico hebben om een ADL beperking te ontwikkelen in vergelijking 
met ouderen die geen infectie doormaakten. Dit gold alleen voor ouderen die nog geen ADL 
beperkingen hadden. Er werd echter geen verschil gevonden voor 86-jarigen die al wel een 
ADL beperking hadden. Naast goede behandeling van infecties, is ook actieve aandacht voor 
het herstel van functioneren wellicht belangrijk om beperkingen in ADL te herstellen.
Om effectieve preventieve maatregelen tegen infecties te kunnen nemen, moeten echter 
vooral die ouderen worden geselecteerd die een verhoogd risico lopen op een urinewegin-
fectie. Daarom werd in hoofdstuk 4 onderzocht welke voorspellende factoren van een urine-
weginfectie bij de oudste ouderen in de algemene bevolking bestaan. Deze studie maakte 
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ook gebruik van gegevens uit de Leiden 85-plus Studie. De studie toonde aan dat vanaf de 
leeftijd van 86 jaar, cognitieve stoornissen, ADL beperkingen, zelf gerapporteerde urine in-
continentie en een urineweginfectie in het voorgaande jaar onafhankelijke voorspellende 
factoren zijn van een toename van het aantal urineweginfecties. Deze voorspellers kunnen 
worden gebruikt voor de ontwikkeling van een klinische predictieregel om ouderen te selec-
teren die baat kunnen hebben bij preventieve maatregelen.
deel 2: de CrAnBerrY studie
Tot nu toe zijn er, naast algemene hygiënische maatregelen, voldoende inname van vocht, 
regelmatig toiletbezoek en het voldoende ledigen van de blaas, geen niet-antibiotische inter-
venties bekend die een afname van urineweginfecties bij verpleeghuisbewoners laten zien. 
Er is echter toenemend bewijs dat het gebruik van cranberry producten kan leiden tot een 
vermindering van het aantal urineweginfecties over een periode van 12 maanden. Ondanks 
dat twee studies aangeven dat cranberrysap beschermend kan werken bij ouderen, is de 
effectiviteit van het gebruik van cranberry capsules ter preventie van urineweginfecties bij 
verpleeghuisbewoners nog niet eerder onderzocht. Daarom is de CRANBERRY studie opgezet.
De CRANBERRY studie is een dubbelblinde gerandomiseerde placebo-gecontroleerde 
studie die plaats heeft gevonden in 21 verpleeghuizen van het Universitair Netwerk voor de 
Caresector in Zuid-Holland (UNC-ZH). Om te bepalen of het gebruik van cranberry capsules 
een doelmatige interventie is ter preventie van urineweginfecties, zijn in de CRANBERRY stu-
die zowel de effectiviteit als de kosten van het gebruik van cranberry capsules onderzocht.
In totaal hebben 928 verpleeghuisbewoners (225 mannen en 703 vrouwen) ouder dan 65 
jaar aan de CRANBERRY studie meegedaan. De deelnemers werden bij aanvang van de studie 
ingedeeld op het risico van het krijgen van een urineweginfectie. Verondersteld werd dat ver-
pleeghuisbewoners met langdurige blaaskatheterisatie, diabetes mellitus, en het gehad heb-
ben van ten minste één urineweginfectie in het jaar voorafgaande aan de studie, een hoog 
risico hebben op een urineweginfectie. Alle andere verpleeghuisbewoners behoorden tot de 
laag risico groep.
Door loting zijn de deelnemers ingedeeld in twee groepen. Een groep kreeg cranberry 
capsules, de andere groep een niet te onderscheiden placebo capsule (dat is een capsule met 
niet-werkzame bestanddelen). De deelnemers kregen twee keer per dag een cranberry of pla-
cebo capsule voor een periode van 12 maanden.
De primaire uitkomstmaat in de studie was de incidentie van urineweginfecties. Omdat het 
vaststellen van een urineweginfectie bij verpleeghuisbewoners lastig is, gebruikte de CRAN-
BERRY studie niet alleen de geldende wetenschappelijke gouden standaard (strikte definitie), 
maar ook de bij iedere individuele patiënt klinisch gebruikte diagnose (klinische definitie). De 
strikte definitie is gebaseerd op een wetenschappelijke benadering, waarbij altijd sprake is 
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van de aanwezigheid van klinische symptomen en de aanwezigheid van bacteriën in de urine. 
De klinische definitie varieert per patiënt en is daardoor een brede en praktische definitie die 
bestaande richtlijnen volgt, die gebaseerd zijn op klinische overeenstemming tussen profes-
sionals, voor het vaststellen van een urineweginfectie bij verpleeghuisbewoners. 
In hoofdstuk 5 wordt de werkzaamheid van cranberry capsules ter preventie van urine-
weginfecties bij verpleeghuisbewoners beschreven. Uit de CRANBERRY studie blijkt dat door 
het gebruik van cranberry capsules het aantal klinische urineweginfecties met 26% vermindert 
bij verpleeghuisbewoners met een hoog risico op een urineweginfectie. Dit behandeleffect 
treedt op na 2 maanden capsule gebruik. Bij meer dan 20% van de bewoners ontwikkelen 
zich helemaal geen urineweginfecties meer. Er is geen verschil gevonden bij verpleeghuis-
bewoners met een laag risico. Voor urineweginfecties die gedefinieerd zijn volgens de strikte 
definitie wordt geen verschil gevonden in het aantal urineweginfecties tussen bewoners die 
cranberry of placebo capsules hebben gebruikt.
Een onderzoek naar het gebruik van cranberry capsules vereist naast een evaluatie van 
de werkzaamheid ook onderzoek naar de kosteneffectiviteit. Daarom is in een economische 
evaluatie in hoofdstuk 6 beschreven wat de effecten zijn van klinische urineweginfecties op 
de gezondheid en kosten, en of het preventief gebruik van cranberry capsules in verpleeghui-
zen kosteneffectief is. Deze studie laat zien dat het gebruik van cranberry capsules door ver-
pleeghuisbewoners met een hoog risico, in de huidige dosering en frequentie waarschijnlijk 
niet kosteneffectief is. Met andere woorden, het gebruik van cranberry capsules vermindert 
wel het aantal klinische urineweginfecties bij verpleeghuisbewoners, maar kost meer dan de 
reguliere behandeling van klinische urineweginfecties.
Hoofdstuk 7 presenteert een algemene discussie over de belangrijkste bevindingen uit 
de studies die beschreven zijn in dit proefschrift. Verder wordt gereflecteerd op het stellen 
van de diagnose urineweginfectie in kwetsbare ouderen met dementie. Ook worden klinische 
implicaties van de bevindingen voor de dagelijkse praktijk in de verpleeghuiszorg gegeven 
en aanbevelingen gedaan voor toekomstig onderzoek. Tenslotte wordt de preventieve zorg 
voor de kwetsbare oudste ouderen in een breder perspectief geplaatst en de uitdagingen en 
barrières van onderzoek in de verpleeghuiszorg besproken.
Uit de eerste drie studies die in dit proefschrift beschreven zijn, blijkt dat klinische urine-
weginfecties vaak voorkomen bij oudste ouderen en dat deze infecties nadelige gevolgen 
kunnen hebben voor het dagelijks functioneren van oudste ouderen die nog niet beperkt zijn 
hun functioneren. Daarnaast blijkt dat de meerderheid van de verpleeghuisbewoners relatief 
stabiel blijven in hun zorgafhankelijkheid. Het is belangrijk om oudste ouderen met een ver-
hoogd risico op het ontwikkelen van een klinische urineweginfectie op te sporen. Dat blijkt 
ook mogelijk te zijn.
Uit de CRANBERRY studie blijkt dat het gebruik van cranberry capsules (tweemaal daags) 
effectief is in het voorkomen van klinische urineweginfecties bij verpleeghuisbewoners met 
een hoog risico op het ontwikkelen van urineweginfecties. Als er minder urineweginfecties 
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zijn, worden daarmee ook ziektedagen en de negatieve gevolgen van een urineweginfectie 
voorkomen. Dat betekent voor de verpleeghuisbewoner minder ongemak. Het gebruik van 
de cranberry capsules bleek echter niet kosteneffectief te zijn. Niettemin, om redenen van 
effectiviteit is het nog steeds aan te raden om verpleeghuisbewoners met een hoog risico op 
urineweginfecties, preventief te behandelen met cranberry capsules.
Omdat de diagnostiek van urineweginfecties bij ouderen met dementie lastig is, gebruikte 
de CRANBERRY studie niet alleen de geldende wetenschappelijke gouden standaard, maar 
ook een klinisch diagnose. De wetenschappelijke ‘gouden standaard’ voor de diagnose van 
een urineweginfectie bestaat uit het vaststellen van de aanwezigheid van klinische symp-
tomen van een urineweginfectie, het opsporen van de veroorzakende bacterie en onder-
zoek naar de aanwezigheid van kenmerken van een ontsteking. Factoren zoals een moeilijke 
patiënt-dokter communicatie door (gevorderde) dementie, het vaak voorkomen van inconti-
nentie, chronische klachten van de urinewegen en vaak positieve urinekweken (bacteriurie) 
zonder dat duidelijk is of deze bacteriën uit de blaas of na urinelozing uit de omgeving af-
komstig zijn, maakt het vaststellen van een urineweginfectie in deze groep kwetsbare oudste 
ouderen moeilijk. De geldende wetenschappelijke gouden standaard blijkt hierdoor minder 
goed bruikbaar en kan leiden tot onjuiste maar ook gemiste diagnoses. Daarom zijn de meeste 
richtlijnen voor het vaststellen van een urineweginfectie bij kwetsbare ouderen gebaseerd op 
overeenstemming over gegroepeerde verschijnselen. Een klinische urineweginfectie wordt 
omschreven als de aanwezigheid van specifieke en niet-specifieke klachten en symptomen, 
zoals onder andere pijn bij het plassen (dysurie), verandering in het karakter van urine, en ver-
anderingen in de mentale toestand. Met urineonderzoek wordt vervolgens de aanwezigheid 
van nitriet en leukocyten vastgesteld, wat kan duiden op een urineweginfectie. Eventueel 
kan met een urinekweek worden vastgesteld welke bacterie de urineweginfectie veroorzaakt 
en voor welke antibiotica deze bacterie gevoelig is, zodat de behandelend arts weet welk 
antibioticum aan de bewoner kan worden gegeven. 
Hoewel er verschillende klinische richtlijnen beschikbaar zijn om artsen te helpen bij het 
stellen van de diagnose van een klinische urineweginfectie bij verpleeghuisbewoners, is er 
geen eenduidige definitie beschikbaar. De huidige richtlijnen zijn niet optimaal voor de klini-
sche besluitvorming en voor een 100%  bevestiging van een klinische urineweginfectie. Ver-
der onderzoek is nodig om de richtlijnen te verbeteren waarmee klinische urineweginfecties 
bij kwetsbare oudste ouderen beter vastgesteld kunnen worden.
De zorg in verpleeghuizen richt zich vooral op verbetering van kwaliteit van leven, het 
verminderen van de gevolgen van ziekte, en het beperken van ziektelast door het voorkomen 
van complicaties, comorbiditeit (het tegelijk voorkomen van verschillende aandoeningen) en 
beperkingen in het dagelijks functioneren. De preventieve zorg voor de kwetsbare oudste 
ouderen zal zich daarom vooral moeten richten op het voorkomen van verlies van kwaliteit 
van leven en zelfredzaamheid in plaats van op het voorkomen van ziekte en sterfte. Daarnaast 
is het voorkomen van ongemak veroorzaakt door ziekte en beperkingen in het functioneren 
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een ander belangrijk preventiedoel. Omdat de meest kwetsbare oudste ouderen over het al-
gemeen in verpleeghuizen wonen en deze groep ouderen heterogeen van samenstelling is, 
zal altijd een weloverwogen keuze gemaakt moeten worden voor preventie maatregelen. Dit 
betekent dat per individuele verpleeghuisbewoner bekeken moet worden welke preventieve 
maatregelen geschikt zijn. Hierbij zal ook rekening gehouden moeten worden met de wensen 
en voorkeuren van individuele verpleeghuisbewoners zodat gericht en bij het individu pas-
sende preventie aangeboden kan worden. Dit alles vraagt  om specifieke inzichten en solide 
bewijs. Er is daarom aanvullend onderzoek nodig om te onderzoeken of individueel gerichte 
preventie inderdaad effectief is in het voorkomen van verlies van kwaliteit van leven en zelf-
redzaamheid.
Onderzoek in verpleeghuizen vraagt om specifieke kennis en een specifieke infrastructuur. 
Toekomstig onderzoek in verpleeghuizen zou daarom het beste uitgevoerd kunnen worden 
binnen een academisch onderzoeksnetwerk. Binnen een academisch onderzoeksnetwerk, 
zoals het Universitair Netwerk voor de Caresector Zuid-Holland (UNC-ZH), werken zorgprofes-
sionals samen met wetenschappers. Zij ontwikkelen, implementeren en testen initiatieven 
om de kwaliteit van zorg te verbeteren. Binnen de netwerkstructuur zijn de universiteit en 
de praktijk nauw met elkaar verbonden en daardoor hebben zij expertise ontwikkeld met 
betrekking tot het uitvoeren van onderzoek in de complexe zorg voor kwetsbare ouderen in 
verpleeghuizen. Een ander belangrijk voordeel van het netwerk is dat door deze samenwer-
king de onderzoeksresultaten direct in de dagelijkse verpleeghuispraktijk en de opleiding van 
zorgprofessionals kan worden toegepast.
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